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 A la morphine 
 
Prends, s’il le faut, docteur, les ailes de Mercure 
Pour m’apporter plus tôt ton baume précieux! 
Le moment est venu de faire la piqûre 
Qui, de ce lit d’enfer, m’enlève vers les cieux. 
 
Merci, docteur, merci! Qu’importe si la cure 
Maintenant se prolonge en des jours ennuyeux! 
Le divin baume est là, si divin qu’Epicure 
Aurait dû l’inventer pour l’usage des Dieux! 
 
Je le sens qui circule en moi, qui me pénètre! 
De l’esprit et du corps ineffable bien-être, 
C’est le calme absolu dans la sérénité. 
 
Ah! Perce-moi cent fois de ton aiguille fine 
Et je te bénirai cent fois, Sainte Morphine, 
Dont Esculape eût fait une Divinité. 
 
 Jules Verne 
 Poésies inédites, 1886
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Abstract 
Opioids (e.g. morphine) are powerful analgesics that are used clinically to treat a 
variety of pain conditions. However, chronic use of opioids is associated with the 
development of adaptations such as tolerance and dependence, which limit their utility as 
long-term pain therapeutics. Opioids produce analgesia by activating mu () opioid 
receptors that are located on both central and peripheral nerve terminals. The  opioid 
receptor is a G protein-coupled receptor that activates inhibitory heterotrimeric G 
proteins composed of a Gi/o subunit and a  heterodimer via nucleotide exchange. 
Once activated, these G protein subunits modulate the activity of a number of 
downstream effectors, including adenylate cyclase and various ion channels. G protein 
signaling is terminated by the intrinsic GTP hydrolysis of the G subunit, although this 
process is accelerated in vivo by regulator of G protein signaling (RGS) proteins. 
The goal of the work described in this thesis was to evaluate the role of Go 
protein and its regulation by RGS proteins in opioid-mediated behaviors. Go is the most 
abundant Gi/o subtype in the brain and has been shown to couple preferentially to the  
opioid receptor. In addition, individual RGS subtypes have been demonstrated to play 
important roles in opioid-mediated behaviors, but it is not known if endogenous RGS 
proteins exert their effects through direct binding to Gi/o subunits or by some other 
mechanism. To study this, opioid-mediated signaling and behaviors were measured in 
two different transgenic mouse models, one with a one with targeted knockout of Go 
protein (Go knockout mice) and the other with targeted knock-in of an RGS-insensitive 
mutant Go protein (Go RGSi mice). Together, these studies demonstrated that  opioid 
receptor coupling to Go is important for the production of opioid antinociception, and 
that RGS proteins regulate this response by directly interacting with Go subunits. This 
work also showed that Go is protective against morphine tolerance and dependence. 
Overall, these findings suggest that the RGS:Go interface could be a potential target for 
the development of improved analgesics that are devoid of unwanted adaptations.
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  Chapter 1
General Introduction 
Opioid receptors and ligands 
Opioid analgesics are the most commonly prescribed pain medications on the 
market (Melnikova, 2010). Although drugs within this class produce effective analgesia, 
they also elicit several unwanted side effects, including constipation and respiratory 
depression (Harris, 2008). The clinical utility of long-term opioid drug treatment is 
further limited by the development of adaptations such as tolerance, in which larger doses 
of drug are required to produce the desired effect (Buntin-Mushock et al., 2005), and 
dependence, which is manifested as a mild withdrawal syndrome upon drug 
discontinuation (Farrell, 1994). Moreover, opioids modulate brain reward systems, and 
therefore many opioid analgesics carry significant abuse liability (Mendelson et al., 2008; 
Rosenblum et al., 2008). Thus, a better understanding of the cellular mechanisms that 
underlie the behavioral effects of opioids is required in order to identify new targets for 
the development of improved analgesics with reduced side effects. 
Humans have been using opioids for thousands of years in the form of opium, 
which is a crude preparation of the sap from the opium poppy Papaver somniferum. 
Morphine, the primary active component of opium, was originally isolated in 1804 by the 
pharmacist Freidrich Sertürner and was the first plant alkaloid to be successfully purified. 
Opium also contains other active alkaloids including codeine and thebaine that are 
actually the precursors for morphine biosynthesis. Identification of the chemical 
structures of the opium alkaloids allowed for synthesis of many related compounds, 
including the agonists hydrocodone, oxycodone and nalbuphine and the antagonists 
naloxone and naltrexone. In addition, there are a number of fully synthetic opioid 
agonists (e.g. fentanyl, methadone) that produce morphine-like analgesia yet differ 
greatly in structure from the natural alkaloids (Figure 1.1) (Trescot et al., 2008).
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Figure 1.1: Structures of the main opioid ligands utilized in this thesis. 
Morphine is the primary active component of opium and is structurally related to the 
semi-synthetic opioid agonist nalbuphine. Methadone is a fully synthetic opioid agonist 
whose structure is unlike other opium alkaloids. Morphine, methadone and nalbuphine 
exert their antinociceptive effects primarily by activating the  opioid receptor, but 
morphine and nalbuphine have some affinity at other opioid receptors and methadone has 
activity at non-opioid sites. Morphine and methadone are generally considered full 
agonists while nalbuphine is usually described as a partial agonist. DAMGO is a  opioid 
receptor-selective full agonist whose structure is derived from that of the endogenous 
opioid peptide enkephalin. Naloxone, naltrexone and diprenorphine are structurally 
similar to morphine yet act as antagonists of ,  and  opioid receptors. CTAP is a  
opioid receptor-selective antagonist that is not structurally related to the endogenous 
opioid peptides.
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Though the pharmacological actions of opioids have been known for a century 
(Watkyn-Thomas, 1912; Macht et al., 1915), opioid binding sites were not identified until 
the 1970s (Goldstein et al., 1971; Pert and Snyder, 1973; Simon et al., 1973; Terenius, 
1973). Shortly thereafter, three distinct opioid receptors were described, and each 
receptor was named after the agonist or assay system with which it was characterized: the 
mu () receptor for morphine, the kappa () receptor for ketocyclazocine (Martin et al., 
1976), and the delta () receptor for the mouse vas deferens (Lord et al., 1977). 
Identification of the cellular targets of opioid analgesics also led to the discovery of the 
endogenous opioid peptide system comprised of the enkephalins (Hughes et al., 1975), 
the endorphins (Mains et al., 1977), and the dynorphins (Goldstein et al., 1979). The 
structures of the endogenous opioid peptides eventually became the basis for the 







-ol]-enkephalin (DAMGO) (Figure 1.1) (Handa et al., 1981) and the 
-selective agonist [D-Pen
2,5
]-enkephalin (DPDPE) (Mosberg et al., 1983). These ligands, 
as well as the  agonist bremazocine (Romer et al., 1980), were utilized in 
autoradiography studies in rat brain (Mansour et al., 1988) to support the existence of 
three distinct opioid receptor types with separate, yet overlapping, functional roles 
(Dhawan et al., 1996; Kieffer and Evans, 2009). 
Despite the early identification of opioid receptor-selective ligands, opioid 
receptors were classified primarily on the basis of physiology and pharmacology until the 
 receptor was cloned in 1992 (Evans et al., 1992; Kieffer et al., 1992; Kieffer, 1995). 
This was soon followed by the cloning and molecular characterization of  and  opioid 
receptors (Reisine and Bell, 1993; Satoh and Minami, 1995). Later, the nociceptin 
receptor (NOP) was classified as a fourth opioid receptor type based on close amino acid 
sequence homology (Bunzow et al., 1994; Mollereau et al., 1994). Molecular cloning of 
the opioid receptors allowed for a more detailed analysis of opioid receptor anatomy 
(Mansour et al., 1995), as well as the use of gene knockout techniques to more fully 
characterize behavioral responses to opioid agonists (Kieffer, 1999). Although all four 
opioid receptors modulate pain signaling (Mogil and Pasternak, 2001; Martin et al., 
2003), the analgesic effects of morphine – the prototypical opioid agonist – are mediated 
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almost exclusively by the  opioid receptor, as demonstrated using  receptor knockout 
mice (Matthes et al., 1996). 
In simple terms, opioids produce analgesia by blocking incoming pain signals. By 
definition, pain is an experience that includes an affective component, and therefore the 
measurement of pain and analgesia in humans includes both subjective and objective 
measures. Given that subjective measures are not possible in rodents, experimental 
models actually test nociception, which is the basic neuronal processing of noxious 
stimuli (Loeser and Treede, 2008). The measurement of analgesia in animal models is 
therefore referred to as antinociception. The following section will describe our current 
knowledge of nociceptive pathways and discuss how opioids interact with these pathways 
to produce antinociception. 
Opioid antinociception 
Ascending and descending nociceptive pathways 
The concept of nociception has been around for centuries, having first been 
described in 1662 by René Descartes who hypothesized that behavioral responses to 
noxious stimuli were somehow centrally-coordinated. The notion that a neural process 
indeed underlies nociception was solidified by Sir Charles Scott Sherrington who in 1906 
reported the existence of a primary afferent nociceptive neuron, or nociceptor 
(Sherrington, 1906). It is now known that nociception is mediated by specific afferent 
nerve fibers in the periphery whose cell bodies reside in the ganglia and project to the 
spinal cord (Figure 1.2). In particular, lightly myelinated A and unmyelinated C fibers 
are responsible for sensing the majority of noxious stimuli, including mechanical, thermal 
and chemical insults (Julius and Basbaum, 2001). Thus, like other sensory processes, 
nociception occurs when neurons respond to a particular stimulus, in this case tissue 
injury. 
Primary sensory neurons that respond to noxious stimulation transmit nociceptive 
information along a well-defined ascending pathway (Figure 1.2). These primary 
nociceptors synapse in the dorsal horn of the spinal cord onto second-order neurons that 
then carry nociceptive information to higher brain centers including the thalamus and 
cortex (Heinricher and Morgan, 1999; Julius and Basbaum, 2001; Fields, 2004).
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Figure 1.2: Ascending and descending nociceptive pathways and primary sites of 
opioid antinociception. 
A peripheral noxious stimulus is sensed by primary afferent nociceptors (usually A or C 
fibers) whose cell bodies are located in the dorsal root ganglion (DRG) and project to the 
dorsal horn of the spinal cord. Nociceptive information is then relayed by second-order 
neurons to higher brain centers including the thalamus and cortex. These neurons also 
provide feedback at the level of the rostroventral medulla (RVM) and periaqueductal gray 
(PAG). Descending modulation of nociception is controlled by outputs from the cortex, 
hypothalamus (Hypo) and amygdala (Amyg) to the dorsal horn via synapses in the PAG 
and RVM. Primary sites of opioid action are denoted by the presence of the  opioid 
receptor. Major supraspinal sites of opioid antinociception include the PAG and RVM. 
Opioids can also have direct effects within the dorsal horn. Finally, opioids are able to 
elicit antinociception by acting peripherally, either in the DRG or at the site of injury 
itself.
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In addition to the ascending pathway, there is also a well-defined nociception modulating 
circuit that provides descending control of nociception (Figure 1.2). The descending 
pathway is controlled by several supraspinal sites (e.g. cortex, amygdala, and 
hypothalamus), and projections from these higher brain areas modulate the activity of 
primary afferent nociceptors in the dorsal horn via relays through the periaqueductal gray 
(PAG) and rostroventral medulla (RVM) (Heinricher and Morgan, 1999; Fields, 2004). 
Opioid modulation of nociceptive pathways 
In general, the antinociceptive effects of opioids are mediated through actions 
within the descending nociception modulatory pathway. Using microinjection techniques 
in rats, researchers have been able to identify the major brain areas that are responsible 
for generating opioid antinociception (Yaksh et al., 1988). In particular, the most 
important and well-studied supraspinal sites of opioid action are the PAG and RVM 
(Figure 1.2) (Heinricher and Morgan, 1999). Microinjection of the  opioid receptor-
selective agonist DAMGO, but not ligands selective for other opioid receptor types, into 
either the PAG (Smith et al., 1988; Fang et al., 1989) or the RVM (Fang et al., 1986; 
Heinricher et al., 1994) produces significant antinociception. Importantly, both the PAG 
and the RVM express high levels of  opioid receptors (Mansour et al., 1988; Mansour et 
al., 1995). Overall, this work suggests that the  opioid receptor is the main target of 
opioid analgesic drugs in these brain areas.  
The primary effect of opioids acting in the PAG and RVM is to activate 
descending projection neurons which in turn inhibit afferent nociceptors at the level of 
the spinal cord (Heinricher and Morgan, 1999). This is thought to occur via removal of 
tonic GABA inhibition of descending projection neurons, a process known as GABA 
disinhibition (Moreau and Fields, 1986; Chieng and Christie, 1994b; Heinricher and 
Tortorici, 1994). However, there may also be a small contribution from the ability of 
opioids to directly suppress descending neurons that facilitate nociception (Heinricher et 
al., 1992; Chieng and Christie, 1994a). 
In addition to effects on supraspinal sites, opioids can produce antinociception 
through direct actions at the dorsal horn (Cesselin et al., 1999), which also expresses a 
high density of  opioid receptors (Figure 1.2) (Besse et al., 1990). Specifically, there are 
several peptides and transmitters released onto second-order projection neurons that serve 
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to facilitate nociceptive transmission; these include substance P, cholecystokinin, and 
glutamate, among others (Millan, 2002). The primary consequence of opioids acting in 
the spinal cord is to inhibit the release of these neurotransmitters, with the net result of 
decreasing ascending nociceptive transmission (Cesselin et al., 1999). Lastly, opioids can 
also act peripherally to elicit antinociception (Figure 1.2), especially in inflamed tissues 
(Stein and Lang, 2009); this mechanism will not be addressed in the present work. 
Experimental models of nociception in rodents 
Experimental animal models have been used for decades to address mechanisms 
of nociception and antinociception; such models were recently reviewed by Barrot (2012) 
and Le Bars et al. (2001). In general, models of mechanical and thermal nociception 
involve exposure to a noxious stimulus followed by the measurement of a response, such 
as withdrawal latency or threshold to avoidance. In contrast, behavioral scoring is usually 
employed for chemical or inflammatory stimulus modalities, for example in the formalin 
test an experimenter will count the number of paw licks, bites, or shakes following 
intradermal formalin injection. 
The measurement of opioid antinociception has classically been accomplished 
using either the hot plate or the tail flick test, both of which involve the measurement of 
responses to an acute thermal stimulus. The tail flick, or tail withdrawal test was one of 
the first nociceptive tests described (D'Amour and Smith, 1941). To perform the test, the 
animal is first lightly restrained, and then the distal part of the tail is exposed to either a 
water bath or a focused infrared beam. In both cases, the response measured is the latency 
for the animal to flick the tail. The hot plate is another classic nociceptive test (Woolfe 
and MacDonald, 1944; O'Callaghan and Holtzman, 1975). In this test, the animal is 
allowed to move freely atop a heated plate, and the response measured is the latency to 
paw licking or often the latency to any first response (e.g. hind paw shaking, jumping). In 
both the hot plate and the tail flick test, administration of an opioid causes prolongation 
of the response latency, and this is defined as an antinociceptive effect. 
One reason why these tests are utilized so frequently in studies of opioid 
antinociception is because they are highly sensitive to  opioid agonists. This is not 
surprising given that  opioid receptors are located on thermosensitive primary afferent C 
fibers (Scherrer et al., 2009). On the other hand, both the hot plate and the tail flick test 
8 
are faced with a few limitations. In particular, both tests are sensitive to stress and/or 
stress-induced analgesia, which could affect the experimental results. This is especially 
true for the tail flick test, in which animals are generally restrained in order to expose the 
tail to the desired stimulus. However, stress exposure can be reduced by prior habituation 
to the testing apparatus. Another drawback to these tests is that small changes in 
temperature can have large effects on response latency, and therefore the stimulus 
temperature must be accurately maintained. Nevertheless, when properly performed by a 
trained experimenter, both the hot plate and the tail flick test are able to provide stable 
measures of nociception and opioid antinociception. 
There are several additional factors that can affect response latency in either the 
hot plate or the tail flick test; these factors are important to consider when interpreting the 
results of these tests. Since response latency is partially a measure of the time it takes for 
the skin temperature to increase above a certain threshold, anything that affects the rise in 
skin temperature will ultimately influence the observed response latency. The rate of rise 
in skin temperature can be affected by both the type of heat and the stimulus intensity. 
For example in the tail flick test, the rise in skin temperature is much more gradual when 
the tail is exposed to an infrared beam than when it is immersed in a water bath. In the 
hot plate test, the rise in paw temperature can differ depending on the material from 
which the hot plate is constructed. Furthermore, increases or decreases in the stimulus 
intensity, or temperature, can affect both nociceptive and antinociceptive responses in 
these tests.  
In addition to being affected by stimulus perception, response latency is also 
influenced by neuronal processing of the response itself. Specifically, responses in the hot 
plate test are considered supraspinal because they involve the expression of complex, 
coordinated behaviors, such as paw licking or jumping. As such, baseline response 
latencies in the hot plate test generally range from 10 to 20 seconds, depending upon the 
hot plate temperature. In contrast, the response in the tail flick test is primarily a spinal 
reflex. The reflexive nature of the tail flick response is perhaps best illustrated by studies 
in which chronic spinal animals were evaluated in the tail flick test. Despite having a 
short segment of spinal cord removed, these animals retain the ability to produce a tail 
flick response (Irwin et al., 1951). Since spinal transection eliminates both ascending and 
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descending nociceptive pathways, this suggests that the minimal circuit required to elicit 
a tail flick response involves only primary afferent nociceptors, dorsal horn interneurons, 
and efferent motor neurons (Figure 1.2). Thus, baseline tail flick latencies are usually on 
the order of 1 to 5 seconds, depending on the stimulus intensity. Nevertheless, tail flick 
responses can also be modulated by descending projections from supraspinal areas 
(Yaksh and Rudy, 1978), and therefore the tail flick response should not be considered 
exclusively spinal. 
Effects of chronic opioid exposure 
Unfortunately, the chronic use of opioids leads to adaptations that detract from the 
usefulness of these drugs as analgesics. These adaptations, including tolerance and 
dependence, are thought to be mediated by homeostatic and/or compensatory 
mechanisms that serve to counteract the effects of continuous opioid receptor activation 
(Williams et al., 2001; Bailey and Connor, 2005; Christie, 2008). The first of these 
adaptations, tolerance, is defined as a loss of effectiveness of a drug during repeated 
exposure such that increasing doses are needed to produce the desired effect. Tolerance 
occurs for many of the behavioral effects of opioids, but the primary clinical concern is 
the development of analgesic tolerance, which in some cases necessitates dose escalation 
of greater than 10-fold in order to maintain analgesic efficacy (Buntin-Mushock et al., 
2005). In experimental models, antinociceptive tolerance can be observed using standard 
nociceptive tests as a decrease in the ability of opioids to produce antinociception with 
repeated administration. Antinociceptive tolerance to opioids can be observed in rodents 
after only a single treatment, also called acute tolerance (Cochin and Kornetsky, 1964; 
Kornetsky and Bain, 1968). Antinociceptive tolerance continues to develop over more 
long-term opioid administration (Cochin and Kornetsky, 1964), and this can lead to 
prolonged changes within nociceptive pathways, even after drug treatment has stopped 
(Williams et al., 2001). 
Adaptive changes within opioid-sensitive networks also underlie the development 
of opioid dependence (Williams et al., 2001; Bailey and Connor, 2005; Christie, 2008). 
Dependence is defined as an altered homeostasis in which the presence of a drug is 
required to prevent symptoms of withdrawal. In the case of opioid dependence in 
humans, common withdrawal symptoms include nausea and vomiting, sweating, yawning 
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and fatigue, tremors, and diarrhea (Farrell, 1994). Some of these same behaviors (e.g. 
tremors, diarrhea) are observed in rodent experimental models, in addition to jumping 
and wet dog shakes (Way and Loh, 1976; Maldonado et al., 1992). In an experimental 
setting, opioid physical dependence is usually quantified by scoring these and other 
behavioral signs after rapidly precipitating withdrawal with an opioid antagonist, such as 
naloxone (Way and Loh, 1976).  
Though the exact mechanistic basis of opioid dependence is still unknown, studies 
have clearly demonstrated that the development of morphine dependence, like most other 
morphine-induced behaviors, is mediated by the  opioid receptor (Maldonado et al., 
1992; Matthes et al., 1996). Given that both the desired antinociceptive effects and 
unwanted side effects produced by opioids are mediated by a single receptor, viable 
strategies toward developing safer analgesics have attempted to identify differences in 
downstream signaling pathways. 
Opioid receptor signaling 
Opioid receptors belong to the family of seven-transmembrane, G protein-coupled 
receptors (GPCRs). GPCRs convert extracellular signals (e.g. neurotransmitters, 
hormones, etc.) into intracellular responses by coupling to heterotrimeric G proteins 
composed of a G subunit bound to a  heterodimer (Gilman, 1987; Milligan and 
Kostenis, 2006). In the inactive state, the G subunit is bound to the guanine nucleotide 
GDP. Agonist activation of a GPCR leads to a conformational change within the receptor 
that is propagated to the G protein (Chung et al.; Westfield et al., 2011), resulting in the 
exchange of GTP for GDP on the G subunit. This leads to the dissociation of G-GTP 
from the  heterodimer and subsequent modulation of downstream effector proteins 
(Figure 1.3). 
Termination of G protein signaling is achieved via intrinsic hydrolysis of GTP to 
GDP by the GTPase domain of the G subunit, which results in the reassociation of G-
GDP and G. The intrinsic GTP hydrolysis rate for some G subtypes is slow (~2-5 
min
-1
); however, this process is significantly accelerated in vivo by regulator of G protein 
signaling (RGS) proteins, which enhance the GTPase activity of G subunits (De Vries 
et al., 2000; Lan et al., 2000; Ross and Wilkie, 2000; Hollinger and Hepler, 2002). 
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Figure 1.3: Cycle of G protein activation and inactivation at the  opioid receptor. 
Agonist stimulation of the  opioid receptor (1) results in the activation of associated 
heterotrimeric Gi/o proteins via nucleotide exchange (2). Once activated, Gi/o-GTP 
dissociates from the  heterodimer, and both subunits signal to downstream effectors 




), G protein-coupled inwardly-
rectifying K
+
 (GIRK) channels, mitogen-activated protein kinases (MAPKs), and 
phospholipase C (PLC). G protein signaling is terminated by GTP hydrolysis, which is 
enhanced by regulator of G protein signaling (RGS) proteins (4).
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Thus, RGS proteins negatively regulate G protein signaling by decreasing levels of active 
G-GTP and  subunits (Figure 1.3).  
Early stages of G protein signaling, including both the activation and inactivation 
of G proteins, likely play an essential role in the expression of behavioral responses to 
morphine. The remainder of this chapter will review what is known regarding the roles of 
G proteins and RGS proteins in the pharmacology of the  opioid receptor, the primary 
target of the prototypical opioid agonist morphine. 
G proteins and  opioid receptor pharmacology 
Heterotrimeric G proteins are generally defined by the identity of the G subunit, 
and each G protein may associate with one of 5  and one of 12  subunits (Milligan 
and Kostenis, 2006). There exist over 15 genetically distinct G subtypes that are divided 
into four major families based upon structural and functional homology: Gs, Gi/o, 
Gq/11, and G12/13 (Wilkie et al., 1992; Wettschureck and Offermanns, 2005). The  
opioid receptor couples to G proteins of the Gi/o family, including both the pertussis 
toxin (PTX)-sensitive G proteins Go, Gi1, Gi2 and Gi3 and the PTX-insensitive G 
protein Gz (Standifer and Pasternak, 1997; Connor and Christie, 1999). 
It was hypothesized early on that receptor-activated Gi/o proteins were 
responsible for the inhibition of adenylate cyclase (AC) enzymes (Gilman, 1987), and 
that this activity was sensitive to ADP-ribosylation by PTX (Katada et al., 1982). Using 
PTX, it was therefore possible to identify and characterize both Gi (Bokoch et al., 1983; 
Codina et al., 1983) and Go (Neer et al., 1984; Sternweis and Robishaw, 1984) from 
partially purified tissue preparations. Not long after the identification of GI and Go, 
another AC inhibitory G subtype, Gz, was discovered (Fong et al., 1988; Matsuoka et 
al., 1988; Wong et al., 1992). Whereas Gi1-3 proteins are expressed fairly ubiquitously 
(Milligan and Kostenis, 2006), Go and Gz tend to be localized to the brain (Gierschik 
et al., 1986; Worley et al., 1986; Hinton et al., 1990), although Go is also enriched in the 
heart (Huff et al., 1985; Valenzuela et al., 1997). 
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G subtypes and  opioid receptor signaling 
It is well-documented that  opioid receptor coupling to Gi/o proteins produces 
AC inhibition in addition to Ca
2+
 channel inhibition, G protein-coupled inwardly-
rectifying K
+
 (GIRK) channel activation, phospholipase C (PLC) stimulation, and 
mitogen-activated protein kinase (MAPK) activation (Figure 1.3) (Standifer and 
Pasternak, 1997; Law et al., 2000). Using immunoprecipitation techniques, the  opioid 
receptor has been shown to interact with multiple Gi/o subtypes (Chalecka-Franaszek et 
al., 2000). Indeed,  opioid receptor signaling is generally thought to be mediated by all 
Gi/o subtypes indiscriminately, including Gz (Connor and Christie, 1999). This has 
been demonstrated using assays for receptor and/or G protein activity in artificially 
reconstituted systems (Ueda et al., 1988; Stanasila et al., 2000; Massotte et al., 2002), 
heterologous cell expression models (Laugwitz et al., 1993; Chakrabarti et al., 1995; 
Chan et al., 1995; Clark et al., 2006; Clark and Traynor, 2006), and rodent tissue (Murthy 
and Makhlouf, 1996; Garzon et al., 1997a). In contrast, several lines of evidence have 
suggested that the  opioid receptor couples preferentially to Go over other Gi/o 
subtypes. In particular, Go was shown to efficiently mediate  receptor inhibition of 
Ca
2+
 currents in both cells (Hescheler et al., 1987) and dorsal root ganglion (DRG) 
neurons (Moises et al., 1994) . Moreover, knockdown of Go, but not Gi1-3, resulted in a 
significant reduction in DAMGO-mediated inhibition of AC activity in both cells and rat 
striatum (Carter and Medzihradsky, 1993). 
Coupling of the  opioid receptor to Gi/o subunits has also been examined by in 
vivo knockdown of individual Gi/o isoforms in rodents using selective antibodies, 
targeted antisense oligodeoxynucleotides (ODNs) (Garzon et al., 2000), or genetic 
knockout techniques (Jiang et al., 2002; Wettschureck et al., 2004). In general, these 
studies have shown that knockdown of either Gi2 or Gz (intracerebroventricular; i.c.v.) 
results in reduced [
3
H]DAMGO binding to  receptors (Sanchez-Blazquez et al., 1993; 
Rossi et al., 1995) and decreased  opioid-stimulated G protein activation (Garzon et al., 
1994) in the PAG, as well as decreased  opioid inhibition of AC the striatum (Shen et 
al., 1998). In addition, exogenous application of Gi2 protein appeared to reverse the 
deficit in morphine-stimulated G protein activation caused by knockdown of Gi2 
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(Garzon et al., 1999). These data suggest that Gi2 and/or Gz may be the most important 
Gi/o subtypes for  opioid receptor signaling in vivo. On the other hand, there are 
conflicting reports demonstrating that Go knockout mice exhibit decreased DAMGO-
stimulated G protein activation across several brain regions (Jiang et al., 2001) and 
reduced DAMGO-induced Ca
2+
 current inhibition in DRG neurons (Jiang et al., 1998). 
G proteins and  opioid receptor-mediated behaviors  
The same in vivo knockdown and knockout techniques have also been applied to 
study the function of Gi/o subunits in  opioid-induced behaviors (Table 1.1). 
Evaluation of morphine antinociception in the tail flick test in either mice or rats with 
reduced Gi/o protein expression has also implicated Gi2 and/or Gz in the control of  
opioid-induced spinal antinociception (Sanchez-Blazquez et al., 1993; Raffa et al., 1994; 
Rossi et al., 1995; Sanchez-Blazquez et al., 1995; Raffa et al., 1996; Standifer et al., 
1996; Shen et al., 1998; Garzon et al., 1999; Sanchez-Blazquez et al., 1999; Yoburn et 
al., 2003). However, there are again conflicting reports in the literature suggesting that 
Go is the primary Gi/o subtype mediating morphine antinociception in the tail flick test 
(Standifer et al., 1996; Karim and Roerig, 2000). Moreover, when Gz was completely 
knocked out in mice, there was either no change (Hendry et al., 2000) or a small decrease 
(Yang et al., 2000; Leck et al., 2004) in morphine antinociception in the hot plate test. 
Thus, there are clearly inconsistencies in our understanding of the contribution of 
individual Gi/o isoforms to  receptor-mediated antinociception; Chapter 2 of this thesis 
attempts to address these discrepancies by evaluating opioid antinociception in a single, 
reproducible mouse model using two noxious tests. 
Though there are only a few reported studies that evaluate the role of Gi/o 
proteins in the development of adaptations following chronic opioid exposure, these 
publications generally report consistent results. In particular, morphine antinociceptive 
tolerance appears to be reduced by knockdown of Gi2 (Garzon and Sanchez-Blazquez, 
2001; Yoburn et al., 2003) but enhanced by knockout of Gz (Hendry et al., 2000; Leck 
et al., 2004), suggesting that Gi2 is protective against morphine tolerance while Gz is 
facilitative. 
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(tail flick test)  
Antisense ODN 
knockdown 
Gi1 No change (Raffa et al., 1994; 
Sanchez-Blazquez 
et al., 1995; Raffa 
et al., 1996; 
Standifer et al., 
1996; Shen et al., 
1998; Sanchez-
Blazquez et al., 
1999; Karim and 
Roerig, 2000; 
Yoburn et al., 2003) 
Gi2 ↓ 
Gi3 No change 
Go ↓ / No change 
Gz ↓ / No change 
Gene knockout Gz No change 




(hot plate test) 
Gene knockout Gz ↓ / No change 
(Hendry et al., 
2000; Yang et al., 















Gene knockout Gz ↑ 
(Hendry et al., 













Gi2 No change (Raffa et al., 1996) 





Gi2 No change (Raffa et al., 1996) 
 
↓, decrease; ↑, increase; ODN, oligodeoxynucleotide
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With regards to morphine dependence, knockdown of Go, Gz, or Gi2 reduced the 
severity of opioid antagonist-precipitated withdrawal (Sanchez-Blazquez and Garzon, 
1994; Garzon and Sanchez-Blazquez, 2001; Kest et al., 2009), suggesting that Gi/o 
signaling does play a role in this adaptation but that more than one Gi/o isoform may be 
involved. Chapter 4 of this thesis is focused on better understanding the role of the Gi/o 
subtype Go in both morphine tolerance and dependence. 
RGS proteins and  opioid receptor pharmacology 
Although  opioid receptor activation of G proteins initiates signaling, the 
receptor and G protein are also regulated by the activity of RGS proteins. There are over 
30 known proteins that contain the conserved RGS homology (RH) domain; these are 
divided into several families based upon the structure of the RH domain and the presence 
of other protein-protein binding domains (Ross and Wilkie, 2000). 
“Canonical” RGS proteins of the R4, RZ, R7 and R12 families (Figure 1.4) are 
best-known for their ability to serve as GTPase-accelerating proteins, or GAPs, for G 
subunits by enhancing GTP hydrolysis and reducing the lifetime of activated G (Figure 
1.3). Structural characterization of G:RGS complexes has revealed that RGS proteins 
enhance GTP hydrolysis by binding to active G-GTP proteins and stabilizing the 
transition state during GTP hydrolysis (Tesmer et al., 1997). Whereas the smaller RGS 
proteins (R4 and RZ families) function primarily as GAPs, some of the larger RGS 
proteins (R7 and R12 families) have been shown to serve additional regulatory functions 
that are mediated through various protein-protein interacting domains. These activities 
include scaffolding, facilitation of G protein signaling, regulation of non-G protein 
signaling, and signal transduction at non-GPCRs (Hollinger and Hepler, 2002; Sethakorn 
et al., 2010). “Non-canonical” RGS proteins of the RA and RL families, including G 
protein-coupled receptor kinase 2 (GRK2), contain an RH domain yet do not possess 
GAP activity. However, these proteins are also able to regulate GPCR signaling by 
directly interacting with and/or scaffolding G proteins (Sethakorn et al., 2010). 
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Figure 1.4: Basic domain structures of the “canonical” regulator of G protein 
signaling (RGS) proteins from the R4, RZ, R7 and R12 families. 
Shown for each family is the common domain structure with the N-terminus oriented to 
the left, as well as a list of individual family members. The R4 and RZ families contain 
relatively simple RGS proteins, with short N- and C-terminal extensions. R4 family 
members contain the RGS homology (RH) domain, together with a short N-terminal 
amphipathic helix. The RZ family is comprised of proteins with an N-terminal cysteine 
string (Cys) preceding the conserved RH domain. The R7 and R12 families are more 
complex, and contain several domains for protein-protein interaction in addition to the 
RH domain. Members of the R7 family contain both a DEP (Disheveled, Egl-10, 
Pleckstrin) domain with a helical extension (DHEX) and a GGL (G protein gamma-like) 
domain. The R12 family contains proteins with a PDZ (PSD95, Dlg1, ZO-1) domain, a 
phosphotyrosine binding (PTB) domain, two Ras binding domains (RBD), and a GoLoco 
motif that binds G-GDP subunits.
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Contribution of individual RGS isoforms 
Approaches utilizing knockdown, overexpression, or constitutive gene knockout 
of individual RGS proteins have demonstrated the importance of these regulatory 
proteins for  opioid receptor signaling and behavior (Kimple et al., 2011). RGS4, a 
member of the R4 family of RGS proteins (Figure 1.4), functions as a negative regulator 
of  opioid receptor signaling in heterologous expression systems. For example, in 
HEK293 cells expressing the  opioid receptor, introduction of RGS4 has been shown to 
reduce  agonist-mediated inhibition of AC and activation of MAPK (Garnier et al., 
2003; Georgoussi et al., 2006; Xie et al., 2007; Leontiadis et al., 2009; Talbot et al., 
2010). However, RGS4 knockout mice do not exhibit changes in morphine 
antinociception or antinociceptive tolerance (Grillet et al., 2005; Han et al., 2010). In 
contrast, knockout of RGS9-2, a member of the R7 family (Figure 1.4), resulted in 
increased morphine antinociception in the hot plate test (Zachariou et al., 2003b), 
suggesting that RGS9-2 negatively regulates  opioid receptor-mediated antinociception. 
RZ and R12 family RGS proteins (Figure 1.4) have not been studied in great detail, 
although there are isolated reports. In particular, ODN knockdown (i.c.v.) of RZ family 
RGS proteins, including RGS17, 19, and 20, resulted in enhanced morphine 
antinociception and antinociceptive tolerance (Garzon et al., 2004; Garzon et al., 2005; 
Sánchez-Blázquez et al., 2005). Alternatively, knockdown of RGS12 (R12 family) was 
shown to increase  opioid antinociception (Garzon et al., 2001; Garzon et al., 2003). 
Role of endogenous RGS proteins 
RGS proteins have been hypothesized to show varying degrees of selectivity for 
specific GPCRs, G proteins, and/or signaling pathways (Ross and Wilkie, 2000), yet it is 
often difficult to observe phenotypic effects of eliminating a single RGS protein due to 
the diversity of the mammalian RGS proteins family (Grillet et al., 2005). Therefore, 
some evidence demonstrating that RGS proteins regulate  opioid receptor signaling 
comes from studies using RGS-insensitive (RGSi) mutant Gi/o proteins (Traynor, 2011). 
A mutant G protein resistant to RGS GAP activity was initially discovered in yeast 
(DiBello et al., 1998). This mutation, a Gly to Ser substitution at amino acid position 183 
in Gi1 (or the analogous position in other Gi/o subtypes), does not alter intrinsic 
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GTPase activity yet prevents RGS protein binding and GAP activity (Lan et al., 1998). 
Thus, evaluation of signaling mediated by RGSi Gi/o proteins in cell systems (Clark and 
Traynor, 2004; Fu et al., 2004) or in vivo (Kaur et al., 2011) can illuminate the role of 
endogenous RGS proteins in a response or behavior of interest. 
The majority of the work utilizing RGSi Gi/o proteins in the context of  opioid 
receptor signaling has evaluated cellular responses to  agonists in heterologous 
expression systems. In cells expressing RGSi Go subunits, endogenous RGS proteins 
negatively regulate  opioid receptor signaling to AC and MAPK (Clark et al., 2003; 
Clark et al., 2008). In the absence of RGS regulation of Go, the  receptor agonists 
morphine and DAMGO produced increased levels of cellular tolerance (Clark and 
Traynor, 2005) and dependence, as measured by AC supersensitization (Clark et al., 
2004), indicating that RGS-mediated inactivation of G subunits is protective against 
these adaptations. Chapter 3 of this thesis furthers these preliminary studies by evaluating 
antinociceptive responses to opioids in mice that express RGSi Go protein. 
Overall goal and specific aims 
The overall goal of the work described in this thesis is to better understand the 
role of the G subunit Go in the behavioral effects of morphine and other opioids acting 
at the  receptor. Go is the most abundant Gi/o subtype expressed in the brain 
(Gierschik et al., 1986) and is therefore poised to play an important role in signaling 
pathways activated by neurotransmitter GPCRs, including the  opioid receptor (Brown 
and Sihra, 2008; Jiang and Bajpayee, 2009).Moreover, although RGS proteins are known 
to play important roles in  opioid receptor-mediated behaviors (Traynor, 2011), it is not 
known whether this is mediated via direct interaction with Gi/o proteins or through 
another RGS protein function, such as scaffolding. Given that RGS proteins have been 
proposed as targets for the therapeutic management of nociception (Neubig and 
Siderovski, 2002), a better understanding of the relationship between  opioid receptors, 
Go proteins and RGS proteins will aid the development of improved analgesics that are 
devoid of deleterious side effects. In particular, this work will further inform drug 
development strategies that exploit the receptor and G protein selectivity of RGS proteins 
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and/or the ability of RGS proteins to exert greater control over the effects of partial 
agonists (Clark et al., 2008). 
Aim 1: To determine the role of Go in  opioid-induced antinociception. 
The first data chapter of this thesis (Chapter 2) addresses the contribution of Go 
subunits to the antinociceptive effects of morphine and other opioid agonists. Though 
Go is the most abundant Gi/o subtype in the brain (Gierschik et al., 1986), previous 
studies utilizing ODN knockdown of individual G isoforms (i.c.v.) have implicated 
Gi2 and/or Gz in the control of  opioid receptor-mediated signaling and behavior 
(Garzon et al., 2000). However, these studies have reported inconsistent results, which is 
not surprising given that the effectiveness of ODN knockdown strategies can vary across 
brain regions, mice and/or experiments (Standifer et al., 1996; Connor and Christie, 
1999). Thus, the studies in this chapter utilize a transgenic mouse that constitutively lacks 
expression of Go protein as a model in which the manipulation of the G isoform is 
consistent. These mice were evaluated for the ability of several  opioid agonists, 
including morphine, methadone, and nalbuphine, to produce antinociception against 
noxious thermal stimuli using the hot plate test and/or the warm-water tail withdrawal 
test. To determine the contribution of Go to  opioid receptor signaling in vivo, 
homogenates prepared from whole brain or spinal cord of mice lacking Go protein were 
evaluated for  opioid receptor and G protein expression levels, as well as  opioid 
agonist-stimulated G protein activation. 
Aim 2: To evaluate how endogenous RGS regulation of Go contributes to  opioid-
induced antinociception.  
Chapter 3 of this thesis evaluates the hypothesis that endogenous RGS proteins 
regulate  opioid antinociception by interacting with Go. The studies in this chapter 
utilize a novel knock-in mouse model that expresses the RGSi mutant Go protein, 
Go
G184S
. Given the high level of redundancy within the RGS family, knockout of 
individual RGS isoforms often produces qualitatively minor and/or inconsistent results 
(Grillet et al., 2005). In contrast, this issue of redundancy is eliminated in mice 
expressing RGSi Go subunits because the G protein of interest is insensitive to the 
actions of all endogenous RGS proteins. Mice expressing RGSi Go protein were tested 
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for the ability of morphine or methadone to induce antinociception using the hot plate test 
and/or the tail withdrawal test. In addition, the ability of morphine and [Met
5
]-enkephalin 
(ME) to modulate GABAergic neurotransmission in the PAG was examined as a 
biochemical correlate of antinociception. Finally, homogenates prepared from whole 
brain or spinal cord of mice expressing RGSi Go protein were evaluated for  opioid 
receptor expression, G protein expression, and  opioid agonist-stimulated G protein 
activation to determine whether the RGSi mutation had any effect on  opioid signaling 
in vivo. 
Aim 3: To examine the role of Go in morphine tolerance and dependence. 
Using the same transgenic mouse model as in Aim 1 that lacks Go protein 
expression, the final data chapter of this thesis (Chapter 4) examines the involvement of 
Go in the development of tolerance and dependence following chronic exposure to 
morphine. The role of individual G subunits in the development of adaptations 
following chronic morphine exposure has not been extensively studied. Thus, the goal of 
the studies in this section was to characterize the role of one G isoform, Go, in 
morphine tolerance and dependence in a comprehensive manner. In particular, mice with 
reduced Go expression were administered repeated injections of morphine and then 
evaluated for the development of morphine antinociceptive tolerance in the hot plate test 
and the expression of morphine dependence by measuring the severity of opioid 
antagonist-precipitated withdrawal. In addition,  opioid receptor expression and  
opioid agonist-stimulated G protein activation were determined in several brain regions 
to evaluate if chronic morphine exposure alters  opioid signaling pathways and whether 
any observed changes are dependent upon Go.
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Chapter 2  





Opioid analgesics elicit their effects via activation of the  opioid receptor, a 
GPCR known to interact with Gαi/o-type G proteins. Work in vitro has suggested that the 
 receptor couples preferentially to the abundant brain Gαi/o isoform, Gαo. However, 
studies in vivo evaluating morphine-mediated antinociception have not supported these 
findings. The aim of the present work was to evaluate the contribution of Gαo to  
receptor-dependent signaling by measuring both antinociceptive and biochemical 
endpoints in a Gαo null transgenic mouse strain. Male wild type and Gαo heterozygous 
null (Gαo +/-) mice were tested for opioid antinociception in the hot plate test or the 
warm-water tail withdrawal test as measures of supraspinal or spinal antinociception, 
respectively. Reduction in Gαo levels attenuated the supraspinal antinociception produced 
by morphine, methadone and nalbuphine, with the magnitude of suppression dependent 
upon agonist efficacy. This was explained by a reduction in both high-affinity  receptor 
expression and  agonist-stimulated G protein activation in whole brain homogenates 
from Gαo +/- and Gαo homozygous null (Gαo -/-) mice, compared with wild type 
littermates. On the other hand, morphine spinal antinociception was not different between 
Gαo +/- and wild type mice and high-affinity  receptor expression was unchanged in 
spinal cord tissue. However, the action of the partial agonist nalbuphine was 
compromised, showing that reduction in Gαo protein does decrease spinal 
antinociception, but suggesting a higher Gαo protein reserve. These results provide the 
                                                 
This work was originally published in Neuropsychopharmacology. Lamberts JT, Jutkiewicz EM, 
Mortensen RM, Traynor JR. Mu-opioid receptor coupling to Go plays an important role in opioid 
antinociception. Neuropsychopharmacology 2011; 36:2041-53. © 2011 Nature Publishing Group. 
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first in vivo evidence that Gαo contributes to maximally efficient  opioid receptor 
signaling and antinociception.  
Introduction 
Opioid analgesics are prescribed for the management of moderate to severe pain. 
Clinically used opioids elicit their effects by stimulation of the  opioid receptor, a 
member of the GPCR superfamily that interacts with heterotrimeric G proteins (Gαβγ), 
which are defined in terms of the Gα subunit. Specifically, the  receptor couples to Gα 
proteins of the PTX-sensitive Gαi/o family, comprised of Gαo (including splice variants 
Gαo1 and Gαo2), Gαi1, Gαi2 and Gαi3 (Laugwitz et al., 1993; Chakrabarti et al., 1995), as 
well as PTX-insensitive Gαz (Garzon et al., 1997b). In the inactive state, Gαβγ exists in 
complex with the receptor. Upon agonist stimulation, GDP bound to the Gα subunit is 
exchanged for GTP, resulting in dissociation of active Gα-GTP from the Gβγ heterodimer 
(reviewed in Brown and Sihra, 2008); both Gα-GTP and Gβγ modulate effectors 
downstream of the  opioid receptor, including AC (Yu and Sadee, 1988) and calcium 
channels (Hescheler et al., 1987; Moises et al., 1994). It has been shown that specific 
Gαi/o subunits differentially contribute to  receptor-dependent behavioral responses, 
including morphine-mediated antinociception (Raffa et al., 1994; Sanchez-Blazquez et 
al., 2001). However, findings are inconsistent due to the variety of methods and models 
utilized in previous work, such that the contribution of each Gα subunit to these 
responses is controversial. 
Gαo is highly expressed in brain (Gierschik et al., 1986). Multiple lines of 
evidence suggest that opioid agonists can activate  opioid receptor-G protein complexes 
in a non-selective manner, especially in heterologous expression systems (Laugwitz et al., 
1993; Clark et al., 2006; Clark and Traynor, 2006). On the other hand, the -selective 
agonist DAMGO was found to activate Gαo to a greater extent than either Gαi2 or Gαi3 
(Clark et al., 2008). Furthermore, in cultured neurons or neuronal-like cells, the  
receptor has been shown to couple to AC (Carter and Medzihradsky, 1993) and N-type 
Ca
2+
 channels (Hescheler et al., 1987; Moises et al., 1994) primarily via activation of Gαo 
(for review, see Jiang and Bajpayee, 2009). 
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Despite the abundance of Gαo in the brain and evidence from in vitro studies that 
Gαo modulates signaling downstream of the  receptor, together with a recent report that 
Gαo may be involved in opioid dependence (Kest et al., 2009), findings in vivo have 
primarily implicated Gαi2 and/or Gαz proteins as mediators of opioid agonist 
antinociception (Raffa et al., 1994; Sanchez-Blazquez et al., 1995; Standifer et al., 1996; 
Sanchez-Blazquez et al., 2001). These studies utilized mice administered i.c.v. antisense 
ODNs against a specific Gα subunit prior to antinociceptive testing of opioid agonists 
(i.c.v.) in the tail flick test (reviewed in Garzon et al., 2000). However, there are a 
number of inherent difficulties with this technique, including proper verification of the 
extent of protein knockdown. For most of these studies, knockdown of Gα protein did not 
exceed ~50% in peri-ventricular regions (e.g. PAG) (Sanchez-Blazquez et al., 1995), 
while ODNs were less effective in brain regions more distal to the site of infusion (e.g. 
thalamus), presumably due to poor diffusion (Sanchez-Blazquez et al., 1995; Standifer et 
al., 1996). However, in one study, in which greater (~60-80%) knockdown of Gα 
subunits was achieved, ODNs directed against Gαo, in addition to other Gα isoforms, 
suppressed morphine antinociception (Standifer et al., 1996). Clearly, inconsistencies in 
the efficacy and selectivity of Gα protein knockdown complicate the interpretation of 
these studies. This previous work is further limited in that only a single measure of opioid 
antinociception was evaluated. 
The present study was designed to test the hypothesis that  opioid receptor 
coupling to Gαo is necessary for opioid antinociception using a constitutive Gαo knockout 
mouse strain (Duan et al., 2007). To probe the role of Gαo in  receptor-mediated 
antinociception, opioid spinal and supraspinal antinociception were evaluated in response 
to noxious thermal stimuli; this is the first time that mice null for Gαo have been 
evaluated for alterations in  receptor-dependent antinociception. Furthermore, to directly 
relate changes in opioid antinociception to alterations in  opioid receptor function, 
membrane homogenates from either whole brain or spinal cord of Gαo transgenic mice 
were evaluated for  opioid receptor expression and  agonist-stimulated G protein 
activity. These studies demonstrate that the abundant brain G protein, Gαo, is the primary 




Transgenic mice null for Gnao1, Gnai2 or Gnai3 were generated as previously 
described (Mortensen et al., 1992; Sowell et al., 1997; Duan et al., 2007) and were 
backcrossed onto the 129S6/SvEvTac (129S6) strain for four generations. Transgenic 
mice and wild type littermates were obtained by heterozygous breeding to control for 
genetic background. Adult, opioid-naïve male mice, matched for age, were utilized for all 
experiments. Mice were group-housed with food and water available ad libitum. Lights 
were maintained on a 12-h light/dark cycle (lights on at 7:00), and all testing was 
performed during the light phase. Studies were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals as adopted by the National Institutes of 
Health and all experimental protocols were approved by the University of Michigan 
Committee on the Use and Care of Animals. 
Antinociceptive tests 
The hot plate test was used to evaluate supraspinal antinociception. Mice were 
given two injections of saline (intraperitoneal; i.p.) to determine baseline latency, 
followed by three cumulative doses of agonist (i.p.) in 15 min intervals (nalbuphine) or 
30 min intervals (morphine, methadone). Where four doses of drug were used, dose-
effect curves were generated by pooling data from two overlapping, cumulative dose-




C hot plate at the appropriate 
interval following each injection and the latency to lick forepaw(s) or jump was measured 




C hot plate temperatures, 
respectively, in order to prevent tissue damage.  
The warm-water tail withdrawal test was used to evaluate spinal antinociception. 
Mice were given a single injection of saline (i.p.) to determine baseline latency, followed 
by four cumulative doses of agonist (i.p.) in 15 min intervals (nalbuphine) or 30 min 





warm-water bath at the appropriate interval following each injection and the latency to 





respectively, in order to prevent tissue damage. 
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For both antinociceptive tests, agonist-stimulated antinociception is expressed as 
percent maximum possible effect (% MPE), where % MPE = (post-drug latency − 
baseline latency) ÷ (cutoff latency − baseline latency) × 100. 
Membrane preparation 
Mice were euthanized by cervical dislocation. Whole brain tissue, minus 
cerebellum, or thoracic and lumbar spinal cord was removed, immediately chilled in ice-
cold 50 mM Tris base, pH 7.4, and membrane homogenates were prepared as previously 
described (Lester and Traynor, 2006). Final membrane pellets were resuspended in 50 
mM Tris base, pH 7.4, aliquoted and stored at -80
o
C. Protein content was determined 
using the method of Bradford (Bradford, 1976). 
Western blot analysis 
Membranes from whole brain (20 g protein) were mixed with sample buffer (63 
mM Tris base, pH 6.8, 2% SDS, 10% glycerol, 0.008% bromophenol blue, 50 mM 
dithiothreitol) and separated by SDS-PAGE on 10% (for detection of Gαo, Gαz, Gαi1, 
Gαi2, Gαi3/1 or Gβ1-4) or 15% polyacrylamide gels (for detection of Gγ2). Proteins were 
then transferred to nitrocellulose membranes (Pierce, Rockford, IL) and probed with 
either rabbit polyclonal anti-Gαo (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), 
rabbit polyclonal anti-Gαz (1:200; Santa Cruz), rabbit polyclonal anti-Gαi1 (1:100; Santa 
Cruz), mouse monoclonal anti-Gαi2 (1:1000; Millipore, Billerica, MA), rabbit polyclonal 
anti-Gβ1-4 (1:500; Santa Cruz) or rabbit polyclonal anti-Gγ2 (1:200; Santa Cruz). 
Membranes from spinal cord (20 μg protein) were also evaluated for Gαo protein content, 
as above. All membranes were probed with mouse monoclonal anti-α-tubulin (1:1000; 
Sigma-Aldrich, St. Louis, MO) as a loading control. Membranes were then incubated 
with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary 
antibody (1:10,000; Santa Cruz). Antibody immunoreactivity was detected by enhanced 
chemiluminesence using an EpiChem3 Benchtop Darkroom (UVP, Upland, CA) and 
band densities were quantified using Image J software 
(http://rsbweb.nih.gov/ij/index.html). Specifically, after background chemiluminesence 
was subtracted, G protein band densities were normalized to respective α-tubulin band 
densities and used to calculate expression relative to wild type for each G protein. 
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Radioligand binding assays 
For [
3
H]diprenorphine binding, membranes from whole brain (100 μg protein) or 
spinal cord (100-200 μg protein) were incubated for 60 min at 25
o
C with 4 nM 
[
3
H]diprenorphine in 50 mM Tris base, pH 7.4, with or without the -selective antagonist 
CTAP (300 nM) to define  opioid receptors. For [
3
H]DAMGO saturation binding, 
membranes from whole brain (100 μg protein) were incubated for 60 min at 25
o
C with 
increasing concentrations of [
3
H]DAMGO (0.09-12 nM) in 50 mM Tris base, pH 7.4. 
Membranes from spinal cord (100-200 μg protein) were incubated for 60 min at 25
o
C 
with 12 nM [
3
H]DAMGO in 50 mM Tris base, pH 7.4. For all radioligand binding 
assays, non-specific binding was evaluated in the presence of 10 M naloxone. Reactions 
were stopped by rapid filtration through a Brandel MLR-24 harvester (Brandel, 
Gaithersburg, MD), and bound radioligand was collected on GF/C filtermats (Whatman, 
Kent, UK) and rinsed three times with ice-cold 50 mM Tris base, pH 7.4. Filters were 
dried, saturated with EcoLume scintillation cocktail (MP Biomedicals, Solon, OH) and 




S]GTPγS binding assays 





S]GTPγS) to Gα proteins, membranes from whole brain (10 μg 
protein) or spinal cord (25-50 μg protein) were pre-incubated for 10 min at 25
o
C with or 
without various concentrations of the opioid agonists DAMGO, methadone, morphine or 
nalbuphine in [
35
S]GTPγS binding buffer (50 mM Tris base, pH 7.4, 5 mM MgCl2, 100 
mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, 100 M GDP and 0.4 U/mL adenosine 
deaminase). After pre-incubation, 0.1 nM [
35
S]GTPγS was added and reactions were 
further incubated for 90 min at 25
o
C. For saturation analysis of [
35
S]GTPγS binding, 
membranes from whole brain (10 μg protein) were pre-incubated for 10 min at 25
o
C with 
or without 10 M DAMGO in [
35
S]GTPγS binding buffer, followed by incubation for 90 
min at 25
o
C with 0.1 nM [
35
S]GTPγS, with or without various concentrations of 
unlabeled GTPγS (0.8 – 50 nM). For all [
35
S]GTPγS binding assays, non-specific binding 
was evaluated in the presence of 10 M GTPγS. Binding reactions were stopped by rapid 
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filtration, rinsed three times with ice-cold wash buffer (50 mM Tris base, pH 7.4, 5 mM 
MgCl2, 100 mM NaCl), and bound radioactivity was measured by liquid scintillation 
counting, as above. 
Drugs 
Morphine sulfate was from RTI (Research Triangle Park, NC). Methadone and 
nalbuphine were obtained through the Narcotic Drug and Opioid Peptide Basic Research 
Center at the University of Michigan (Ann Arbor, MI). For behavioral experiments, all 







were purchased from PerkinElmer. Adenosine deaminase was obtained from Calbiochem 
(San Diego, CA). DAMGO, CTAP, GDP, GTPγS and all other chemicals were obtained 
from Sigma-Aldrich, unless otherwise noted. 
Data analysis 
All data were analyzed using GraphPad Prism software, version 5.0 (GraphPad, 
San Diego, CA). Differences between genotypes were evaluated using Students’ t-tests or 
one-way or two-way analysis of variance (ANOVA) with Bonferroni’s post-tests, where 
appropriate. For all statistical tests, significance was set at p<0.05. In vivo potency (50% 
effective dose; ED50) values were calculated by fitting the compiled data to an agonist 
versus normalized response curve (Hill slope=1), and values are expressed as the mean 
(95% confidence interval; CI). Where antinociception was near or below 50% MPE, ED50 
values were extrapolated from the fitted data. Maximal radioligand binding (Bmax) and 
radioligand binding affinity (KD) values were derived by fitting each experiment to a one-
site saturation binding curve fit (Hill slope=1), while maximal [
35
S]GTPγS stimulation 
(maximal agonist-stimulated response; Emax) and in vitro potency (50% effective 
concentration; EC50) values were calculated by fitting individual experiments to an 
agonist versus response curve fit (Hill slope=1); values are expressed as the mean ± 
standard error of the mean (SEM). 
Results 
Characterization of transgenic mice lacking Gαo protein 
The full knockout, Gαo -/- mice did not often survive until weaning (~21 days), whereas 
wild type and Gαo +/- mice were obtained at frequencies predicted by Mendeleian 
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genetics (Table 2.1) (χ
2
=11.07, df=1, p<0.001). Peri-natal lethality was also noted in the 
initial reports of two independently-generated Gαo null mouse strains (Valenzuela et al., 
1997; Jiang et al., 1998). These previous studies also reported several neurological 
abnormalities in Gαo -/- animals, including hyperactivity, tremor and turning behavior; 
however, no such gross behavioral abnormalities were noted for the Gαo +/- or Gαo -/- 
mice used in this study (Duan et al., 2007; unpublished observations). In adulthood (>8 
weeks), body weight varied as a function of genotype (Table 2.1) (F(2,23)=14.54, 
p<0.001). Post hoc analysis revealed that those Gαo -/- mice that did survive weighed 
significantly less than their wild type littermates, whereas Gαo +/- mice did not differ 
from wild type controls. 
Supraspinal antinociception in Gαo transgenic mice 
To determine whether Go is involved in opioid antinociception, Go +/- mice 
were evaluated for morphine antinociception in the hot plate test (Figure 2.1). In the 52
o
C 
hot plate test, the baseline nociceptive threshold was not significantly different between 
wild type (12.6 ± 0.6 s; n=30) and Go +/- mice (12.2 ± 0.5 s; n=32; t(60)=0.4885, 
p=0.627). Morphine produced a dose-dependent increase in antinociception that was 
significantly reduced (~4-fold) in Go +/- mice when compared with wild type controls, 
with ED50 values of 47.7 mg/kg (31.2 – 72.9) and 11.4 mg/kg (5.9 – 22.1), respectively 
(Figure 2.1a). Although there was no significant interaction, there were significant main 
effects of dose and genotype (dose: F(2,36)=19.88; p<0.001; genotype: F(1,36)=15.76, 
p<0.001). 
Increasing the efficacy requirements of the nociceptive system might further 
exaggerate this observed genotype difference; thus, the hot plate temperature was raised 
to 55
o
C and Gαo transgenic mice were again evaluated for morphine supraspinal 
antinociception (Figure 2.1b). As expected, a decreased baseline nociceptive threshold 
was observed at the elevated hot plate temperature, and there were no significant 
differences between wild type (7.5 ± 0.8 s; n=9) and Gαo +/- mice at baseline (6.6 ± 0.6 s; 
n=10; t(17)=0.8940, p=0.384). Morphine dose-dependently produced antinociception in 
both wild type and Gαo +/- mice, but the ED50 was shifted ~6-fold for Gαo +/- mice, with 
a value of 62.7 mg/kg (42.9 – 91.5) compared with 9.9 mg/kg (5.8 – 17.1) for wild type 
littermates (Figure 2.1b).  
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Table 2.1: Physical characteristics of wild type and Gαo transgenic mice. 
 
Genotype Body Weight (g) 
Genotype Frequency at Weaning (%) 
Expected Observed (n=347)
 
Wild type 28.6 ± 1.3 (n=10) 25.0 35.7 (n=124) 
Gαo +/- 27.6 ± 0.8 (n=12) 50.0 59.4 (n=206) 
Gαo -/- 18.2 ± 1.4 (n=4)* 25.0 4.9 (n=17) 
 




Figure 2.1: Supraspinal antinociception produced by morphine, methadone and 
nalbuphine in the hot plate test in Gαo transgenic mice. 
Antinociception was measured in wild type and Gαo +/- mice 30 min following morphine 
in the (a) 52
o
C or (b) 55
o
C hot plate test, (c) 30 min following methadone in the 52
o
C hot 
plate test, and (d) 15 min following nalbuphine in the 52
o
C hot plate test. Data represent 
the mean ± SEM for morphine at 52
o
C (n=7) and 55
o
C (n=9-10), for methadone (n=7-15) 
and for nalbuphine (n=8-10). Legend in panel (a) also describes panels (b) through (d). 
Asterisks indicate a statistical difference versus wild type by Bonferroni’s post-test 
(*p<0.05, **p<0.01, ***p<0.001).
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There were significant main effects of both dose (F(2,51)=25.37; p<0.001) and genotype 
(F(1,51)=41.98, p<0.001), although there was no significant interaction. 
To determine whether Gαo plays a role in the antinociception produced by opioid 
agonists other than morphine, Gαo transgenic mice were evaluated for either methadone 
or nalbuphine antinociception in the 52
o
C hot plate test (Figure 2.1c,d). Like morphine, 
methadone produced a dose-dependent increase in antinociception (Figure 2.1c).The 
ED50 value for wild type mice was 13.0 mg/kg (10.1 – 16.8), which was ~2-fold higher 
than the extrapolated ED50 value for Gαo +/- mice of 5.8 mg/kg (4.4 – 7.6). There was no 
significant interaction; however, there were significant main effects of both dose 
(F(3,82)=33.12, p<0.001) and genotype (F(1,82)=19.87, p<0.001). The partial agonist 
nalbuphine also produced a dose-dependent stimulation of antinociception that was 
significantly reduced for Gαo +/- mice, compared with wild type littermates (Figure 2.1d), 
with an ED50 value of 170.2 mg/kg (108.3 – 267.6) for wild type mice. Extrapolation of 
the dose-response curve for Gαo +/- mice gave an ED50 value of 432.0 mg/kg (289.0 – 
645.9), representing a ~3-fold shift. There were significant main effects of both dose 
(F(2,48)=48.62, p<0.001) and genotype (F(1,48)=11.09; p=0.002), as well as a significant 
dose × genotype interaction (F(2,48)=3.377, p=0.043). 
Spinal antinociception in Gαo transgenic mice 
Gαo transgenic mice were also evaluated in the warm-water tail withdrawal test 
(Figure 2.2), the same antinociceptive measure that was utilized in the majority of 
antisense ODN studies (Raffa et al., 1994; Sanchez-Blazquez et al., 1995; Sanchez-
Blazquez et al., 2001). In the 50
o
C tail withdrawal test, the baseline tail flick latency was 
not significantly different between wild type (3.2 ± 0.4 s; n=13) and Gαo +/- mice (4.2 ± 
0.6 s; n=15; t(26)=1.399, p=0.174). Morphine produced a dose-dependent increase in 
antinociception in both wild type and Gαo +/- mice, with ED50 values of 5.2 mg/kg (2.7 – 
9.8) and 4.1 mg/kg (2.3 – 7.2), respectively (Figure 2.2a). There was a significant main 
effect of dose (F(3,44)=14.79, p<0.001), although the main effect of genotype 
(F(1,44)=0.1024, p=0.751) and the dose × genotype interaction were not significant.
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Figure 2.2: Ability of morphine and nalbuphine to induce spinal antinociception in 
the warm-water tail withdrawal test in Gαo transgenic mice. 
Antinociception was measured in wild type and Gαo +/- mice 30 min following morphine 
in the (a) 50
o
C or (b) 55
o
C warm-water tail withdrawal test and (c) 15 min following 
nalbuphine in the 50
o
C warm-water tail withdrawal test. Data represent the mean ± SEM 
for morphine at 50
o
C (n=6-7) and 55
o
C (n=8) and for nalbuphine (n=7-8). Legend for 
panels (b) and (c) is the same as for panel (a). Asterisks indicate a statistical difference 
versus wild type by Bonferroni’s post-test (*p<0.05, ***p<0.001).
34 
Given that morphine behaves as a full agonist in this test, which may preclude the 
identification of small differences between genotypes, it was hypothesized that increasing 
the efficacy requirement of the system by raising the water bath temperature to 55
o
C 
(Figure 2.2b) should allow for the identification of such differences. Again, as predicted, 
a decreased baseline nociceptive threshold was observed at the elevated water 
temperature, and there were also no significant differences between wild type (1.9 ± 0.1 
s; n=8) and Gαo +/- mice in this test (1.8 ± 0.2 s; n=8; t(14)=0.6932, p=0.500). Against 
the 55
o
C stimulus, morphine produced a dose-dependent increase in antinociception that 
was equivalent between wild type and Gαo +/- mice, with ED50 values of 8.2 mg/kg (5.5 – 
12.5) and 7.4 mg/kg (5.5 – 10.0), respectively (Figure 2.2b). There was no significant 
interaction or significant effect of genotype (genotype: F(1,56)=0.2371, p=0.628), but 
there was a significant main effect of dose (dose: F(3,56)=124.0, p<0.001). 
As an alternative method of evaluating whether the efficacious antinociception 
produced by morphine was masking a mediatory role for Gαo, spinal antinociception was 
measured in the 50
o
C warm-water tail withdrawal test in response to the low-efficacy 
agonist, nalbuphine (Figure 2.2c). Nalbuphine produced a dose-dependent stimulation of 
spinal antinociception that was significantly reduced (~7-fold) in Gαo +/- mice when 
compared with wild type littermates, with wild type mice exhibiting an ED50 value of 
24.2 mg/kg (17.5 – 33.4) (Figure 2.2a). Extrapolation of the nalbuphine dose-response for 
Gαo +/- mice revealed an ED50 value of 176.1 mg/kg (113.3 – 273.8). There were 
significant main effects of dose and genotype (dose: F(3,52)=20.35, p<0.001; genotype: 
F(1,52)=48.62, p<0.001), as well as a significant dose × genotype interaction 
(F(3,52)=3.552, p=0.021). 
Antinociception in Gαi2 and Gαi3 transgenic mice 
To confirm the importance of Gαo for opioid antinociception, transgenic mice 
lacking either Gαi2 (Gαi2 heterozygous null, Gαi2 +/-; Gαi2 homozygous null, Gαi2 -/-) or 
Gαi3 (Gαi3 heterozygous null, Gαi3 +/-; Gαi3 homozygous null, Gαi3 -/-), together with 
their respective wild type littermates, were evaluated in the 52
o
C hot plate and 50
o
C 
warm-water tail withdrawal tests (Figure 2.3).
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Figure 2.3: Morphine supraspinal and spinal antinociception in Gαi2 and Gαi3 
transgenic mice. 
Antinociception produced 30 min following morphine was evaluated in the 52
o
C hot 
plate test in (a) Gαi2 +/- and Gαi2 -/- mice and (b) Gαi3 +/- and Gαi3 -/- mice and in the 
50
o
C warm-water tail withdrawal test in (c) Gαi2 +/- and Gαi2 -/- mice and (d) Gαi3 +/- 
and Gαi3 -/- mice, together with their respective wild type littermates. Data represent the 
mean ± SEM for Gαi2 mice in the hot plate (n=8-10) and tail withdrawal tests (n=6-9) and 
for Gαi3 mice in the hot plate (n=8-9) and tail withdrawal tests (n=6-9). Legends for 
panels (c) and (d) are the same as for panels (a) and (b), respectively.
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Both the Gαi2 and the Gαi3 transgenic mouse strains were generated in parallel with Gαo 
transgenic mice, and inactivation of the appropriate Gα subunit has been previously 
confirmed by Western blot analysis (Sowell et al., 1997; Duan et al., 2007). In the 52
o
C 
hotplate test (Figure 2.3a,b), the baseline response latency was equivalent among all Gαi2 
transgenic mouse genotypes (wild type: 12.0 ± 0.7 s, n=10; Gαi2 +/-: 11.6 ± 0.7 s, n=9; 
Gαi2 -/-: 12.9 ± 0.7 s, n=8; F(2,24)=0.8112, p=0.456).Morphine produced a dose-
dependent increase in antinociception that was not different between wild type, Gαi2 +/- 
and Gαi2 -/- mice, with ED50 values of 9.4 mg/kg (5.8 – 15.3), 12.0 mg/kg (6.9 – 20.8) 
and 10.6 mg/kg (6.0 – 18.8), respectively (Figure 2.3a). There was a significant main 
effect of dose (F(2,72)=59.03, p<0.001), but the main effect of genotype 
(F(2,72)=0.3274, p=0.722) and the dose × genotype interaction were not significant. 
Similarly, in Gαi3 transgenic mice, morphine produced a dose-dependent increase in 
antinociception that was equivalent between wild type, Gαi3 +/- and Gα -/- mice, with 
ED50 values of 13.2 mg/kg (8.5 – 20.4), 10.6 mg/kg (6.0 – 18.9) and 8.1 mg/kg (4.4 – 
15.0), respectively (Figure 2.3b). There was a significant main effect of dose 
(F(2,69)=37.38, p<0.001), but not genotype (F(2,69)=0.7686, p=0.468), and no 
significant interaction. There were also no genotype-dependent differences observed in 
the baseline nociceptive threshold for these mice (wild type: 13.3 ± 1.4 s, n=9; Gαi3 +/-: 
16.8 ± 1.2 s, n=9; Gαi3 -/-: 16.2 ± 1.4 s, n=8; F(2,23)=2.139, p=0.141). 
Gαi2 and Gαi3 transgenic mice were also evaluated for spinal antinociception in 
the 50
o
C tail withdrawal test (Figure 2.3c,d). Baseline response latencies in this test were 
equivalent among all Gαi2 (wild type: 5.0 ± 0.4 s, n=9; Gαi2 +/-: 4.4 ± 0.6 s, n=8; Gαi2 -/-: 
3.9 ± 0.5 s, n=6; F(2,20)=1.050, p=0.368) and Gαi3 transgenic mouse genotypes (wild 
type: 5.6 ± 0.4 s, n=8; Gαi3 +/-: 4.2 ± 0.5 s, n=9; Gαi3 -/-: 4.4 ± 0.8 s, n=6; F(2,20)=1.990, 
p=0.163). Morphine produced a dose-dependent increase in antinociception that was not 
different between wild type, Gαi2 +/- and Gαi2 -/- mice, with ED50 values of 2.2 mg/kg 
(1.6 – 2.9), 2.0 mg/kg (1.6 – 2.6) and 2.2 mg/kg (1.5 – 3.3), respectively (Figure 2.3c). 
There was no significant interaction or main effect of genotype (F(2,80)=0.2412, 
p=0.786), but there was a significant main effect of dose (F(3,80)=113.5, p<0.001). 
Similarly, in Gαi3 transgenic mice, morphine produced a dose-dependent increase in 
antinociception that was equivalent in wild type, Gαi3 +/- and Gαi3 -/- mice, with ED50 
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values of 1.6 mg/kg (1.2 – 2.2), 1.4 mg/kg (1.2 – 1.7) and 2.0 mg/kg (1.4 – 3.1), 
respectively (Figure 2.3d). Although there was no significant interaction or main effect of 
genotype (F(2,80)=1.936, p=0.151), there was a significant main effect of dose 
(F(3,80)=171.1, p<0.001). 
G protein expression in Gαo transgenic mouse brain 
Western blot analysis of G protein expression in whole brain membrane samples 
confirmed the loss of Gαo protein in Gαo -/- mice (Figure 2.4a). Quantification of 
Western blot images for Gαo revealed that, in comparison with wild type controls,       
Gαo +/- mice express ~60% less Gαo protein, which is close to the expected 50% 
reduction (Figure 2.4a). Across a panel of G protein subunits, including Gαi/o, Gβ and Gγ 
proteins (Figure 2.4), the expression of Gαo (Figure 2.4a) (F(2,6)=527.9, p<0.001), Gβ1-4 
(Figure 2.4f) (F(2,6)=46.53, p<0.001) and Gγ2 (Figure 2.4g) (F(2,6)=18.45, p=0.003) 
were significantly decreased as a function of genotype. In contrast, there were no 
compensatory changes noted for the expression of either Gαz (Figure 2.4b) 
(F(2,6)=0.0548, p=0.947), Gαi1 (Figure 2.4c) (F(2,6)=0.6938, p=0.536) or Gαi2 (Figure 
2.4d) (F(2,6)=0.0189, p=0.981). 
 Receptor expression in Gαo transgenic mouse brain and spinal cord 
To evaluate whether the reduction in opioid antinociception observed in Gαo +/- 
mice could be explained by alterations at the receptor level,  opioid receptor expression 
was measured in membranes from whole brain or from spinal cord of Gαo transgenic 
mice (Table 2.2). Binding of a maximal concentration (4 nM) of the radiolabeled opioid 
antagonist [
3
H]diprenorphine, representing the entire pool of ,  and  opioid receptors, 
was unaffected by genotype in either whole brain (F(2,5)=0.3542, p=0.718) or spinal 
cord (t(4)=0.0097, p=0.993). To measure total  receptor expression, maximal 
[
3
H]diprenorphine binding was displaced using the -selective antagonist CTAP (300 
nM). Total  receptor expression was also not different between genotypes (Table 2.2) in 
either whole brain (F(2,5)=0.6832, p=0.547) or spinal cord (t(4)=0.7611, p=0.489). 
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Figure 2.4: G protein expression in whole brain homogenates from Gαo transgenic 
mice. 
Membranes from whole brain of wild type (wt), Gαo +/- (+/-) and Gαo -/- (-/-) mice were 
separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed for the 
expression of (a) Gαo, (b) Gαz, (c) Gαi1, (d) Gαi2, (e) Gβ1-4 or (f) Gγ2 using selective 
antibodies (see Materials and Methods); membranes were also probed for tubulin as a 
loading control. G protein expression was quantified in Image J by normalizing G protein 
band intensity to tubulin band intensity, and data are plotted as a ratio of wt expression. 
Data represent the mean ± SEM (n=3). Symbols indicate a statistical difference versus wt 






p<0.001) by Bonferroni’s 
post-test.
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Table 2.2: Properties of agonist and antagonist radioligand binding in membranes 


















Wild type 366 ± 24 218 ± 13 
b 
246 ± 29 2.5 ± 0.4 
Gαo +/- 391 ± 38 216 ± 3 181 ± 16
 
1.9 ± 0.5 
Gαo -/- 407 ± 38 233 ± 12 121 ± 17*
 
3.5 ± 1.3 
Spinal 
cord 




84 ± 5 
c 
ND 




ND, not determined. 
a
  Receptor expression was evaluated as the amount of bound 
[
3
H]diprenorphine at a maximal concentration that was displaced by the -selective 
antagonist CTAP (300 nM). 
b
 In wild type whole brain, there is a trend for total  
receptor number to be less than high-affinity  opioid receptor number because binding 
was measured indirectly (see Materials and Methods). 
c
 In spinal cord, Bmax values were 
estimated using a single maximal concentration of [
3
H]DAMGO. Data represent the 
mean ± SEM (n=2-3 performed in at least duplicate). Asterisk indicates a statistical 
difference versus wild type whole brain by Bonferroni’s post-test (p<0.05).
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In whole brain, maximal binding (Bmax) of [
3
H]DAMGO (Table 2.2), which, as an 
agonist, recognizes only high-affinity  opioid receptors, was significantly decreased in 
Gαo +/- and Gαo -/- mice when compared with wild type controls (F(2,5)=10.44; 
p=0.016). There was no change across genotypes in the affinity (KD) of [
3
H]DAMGO for 
high-affinity  receptor sites (F(2,5)=1.398; p=0.330). In contrast, maximal (12 nM) 
[
3
H]DAMGO binding was unchanged in the spinal cord of Gαo +/- mice when compared 
with wild type littermate controls (t(4)=1.186, p=0.301). 
G protein activation in Gαo transgenic mouse brain and spinal cord 
To examine the importance of Gαo for  opioid receptor function, the [
35
S]GTPγS 
binding assay was utilized to evaluate the first component of  opioid signaling, namely, 
G protein activation, in membranes from either whole brain or spinal cord of Gαo 
transgenic mice (Figure 2.5;Table 2.3).
 
In whole brain, basal levels of [
35
S]GTPγS 
incorporation (Table 2.3) were significantly reduced in Gαo +/- and Gαo -/- mice, 
compared with wild type littermates (F(2,5)=20.06, p=0.004), suggesting that Gαo is 
responsible for some, but not all, basal G protein activity. The  selective agonist 
DAMGO produced a dose-dependent stimulation of [
35
S]GTPγS binding that was 
reduced in Gαo +/- and Gαo -/- mice when compared with wild type controls (Figure 
2.5a). There was a significant concentration × genotype interaction for this response 
(F(14,39)=6.700, p<0.001), including main effects of both concentration (F(7,39)=43.38, 
p<0.001) and genotype (F(2,39)=72.02, p<0.001). Maximal DAMGO-stimulated binding 
(Emax) (Table 2.3) was decreased in Gαo transgenic mice in a genotype-dependent manner 
(F(2,5)=64.69, p<0.001); this reduction in maximal stimulation was without a change in 
potency (EC50) between wild type and Gαo +/- mice (t(2)=1.307, p=0.321). Morphine 
also produced a dose-dependent stimulation of [
35
S]GTPγS binding that was significantly 
decreased in Gαo +/- and Gαo -/- mice when compared with wild type littermates (Figure 
2.5b). There were significant main effects of both concentration and genotype, as well as 
a significant concentration × genotype interaction (concentration: F(7,39)=15.79, 




Figure 2.5: Ability of opioid agonists to stimulate G protein activity in whole brain 
homogenates from Gαo transgenic mice. 
Agonist-stimulated [
35
S]GTPγS (0.1 nM) binding was measured in the presence of 
various concentrations of the opioid agonists (a) DAMGO or (b) morphine, (c) in the 
presence of 10 M DAMGO plus increasing concentrations of unlabeled GTPγS, and (d) 
in the presence of 10 M DAMGO, methadone, morphine or nalbuphine in membrane 
homogenates from whole brain of wild type, Gαo +/- and Gαo -/- mice. Non-specific 
binding was evaluated in the presence of unlabeled GTPγS (10 M). Data are plotted as 
agonist-stimulated [
35
S]GTPγS binding, defined as the increase in [
35
S]GTPγS 
incorporation in the presence of agonist over that of basal (measured in the absence of 
agonist), and represent the mean ± SEM (n=2-3 performed in at least duplicate). Legend 
in (a) also applies to panels (b) and (c). Symbols indicate a statistical difference versus 













Table 2.3: Properties of agonist-stimulated [
35































Wild type 62.2 ± 2.5 71.3 ± 3.2 287 ± 91 39.4 ± 4.5 165 ± 14 8.31 ± 1.01 14.2 ± 4.0 




4.26 ± 1.31 16.5 ± 6.7 
Gαo -/- 22.2 ± 0.3**
, +










7.1 ± 4.4 
Spinal 
cord 
Wild type 59.0 ± 10.9 46.4 ± 5.4 ND 36.3 ± 4.0 ND ND ND 
Gαo +/- 49.0 ± 11.1 35.0 ± 6.7
#
 ND 19.5 ± 3.1
##
 ND ND ND 
 
NC, not calculated; ND, not determined. Agonist-stimulated [
35
S]GTPγS binding is defined as the increase in [
35
S]GTPγS 
incorporation in the presence of agonist, over that of basal (measured in the absence of agonist). Data represent the mean ± SEM (n=2-
3 performed in duplicate). Symbols indicate a statistical difference versus wild type whole brain (*p<0.05, **p<0.01, ***p<0.001) or 












The Emax for morphine (Table 2.3) was reduced as a function of genotype (F(2,5)=16.24, 
p=0.007), and was accompanied by a non-significant trend toward a reduction in the EC50 
value for Gαo +/- mice, compared with wild type littermates (t(4)=2.407, p=0.074). 
Given that DAMGO-stimulated [
35
S]GTPγS incorporation was significantly 
attenuated, saturation analysis of DAMGO-stimulated binding was performed (Figure 
2.5c; Table 2.3) to measure the maximal number of G proteins (Bmax) activated by 
agonist-occupied  receptors and the ability of agonist to induce formation of GTP-bound 
Gα (KD) (Traynor and Nahorski, 1995; Selley et al., 1997b). In membranes from whole 
brain, DAMGO stimulated [
35
S]GTPγS incorporation was increased as a function of 
increasing concentration of GTPγS, but was significantly reduced in Gαo +/- and Gαo -/- 
mice when compared with wild type controls (Figure 2.5c). There were significant main 
effects of both concentration and genotype, as well as a significant concentration × 
genotype interaction (concentration: F(7,44)=37.50, p<0.001; genotype: F(2,44)=79.22, 
p<0.001; concentration × genotype: F(14,44)=7.482, p<0.001). This reduction was 
manifested as a decrease in Bmax for GTPγS binding (F(2,5)=9.359, p=0.020), without an 
accompanying change in the KD for GTPγS (Table 2.3) (F(2,5)=0.6608, p=0.556).  
[
35
S]GTPγS binding stimulated by a maximal concentration of DAMGO, 
morphine, methadone or nalbuphine was evaluated in whole brain homogenates from Gαo 
transgenic mice (Figure 2.5d). In wild type mice, the opioid agonists tested elicited 
maximal [
35
S]GTPγS stimulation according to the rank order of efficacy DAMGO = 
methadone > morphine >> nalbuphine. When compared with wild type controls, Gαo +/- 
and Gαo -/- mice exhibited a reduction in G protein stimulation across all opioid agonists 
tested, including: DAMGO (wild type: 83.4 ± 9.1 fmol/mg; Gαo +/-: 59.0 ± 7.7 fmol/mg; 
Gαo -/-: 20.1 ± 6.1 fmol/mg; F(2,5)=12.98, p=0.011), methadone (wild type: 82.2 ± 9.9 
fmol/mg; Gαo +/-: 51.2 ± 9.3 fmol/mg; Gαo -/-: 19.6 ± 8.7 fmol/mg; F(2,5)=9.407, 
p=0.020), morphine (wild type: 67.1 ± 5.0 fmol/mg; Gαo +/-: 40.9 ± 5.3 fmol/mg; Gαo -/-: 
10.3 ± 2.3 fmol/mg; F(2,5)=29.93, p=0.002) and nalbuphine (wild type: 17.8 ± 3.0 
fmol/mg; Gαo +/-: 7.7 ± 2.6 fmol/mg; Gαo -/-: 0.01 ± 2.49 fmol/mg; F(2,5)=8.770, 
p=0.035). 
In spinal cord homogenates, basal levels of [
35
S]GTPγS incorporation (Table 2.3) 
were not different between Gαo +/- mice and their wild type littermates (t(4)=0.6431, 
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p=0.555), suggesting that Gαo is not as important for basal G protein activity in the spinal 
cord. DAMGO-stimulated binding (Figure 2.6; Table 2.3) was significantly reduced in 
Gαo +/- mice when compared with wild type controls (t(2)=7.072, p=0.019). Similarly, 
morphine-stimulated [
35
S]GTPγS binding in spinal cord (Figure 2.6; Table 2.3) showed a 
decrease in Gαo +/- mice, as compared with wild type littermates (t(2)=17.54, p=0.003). 
Western blot analysis of Gαo expression in spinal cord membranes confirmed that there 
was a significant reduction in Gαo protein levels in these samples, as compared with the 
loading control tubulin (Figure 2.6, inset). 
Discussion 
This study shows that reduction in the expression of the inhibitory Gα isoform, 
Gαo, attenuates  agonist-mediated antinociception in mice at both the supraspinal and 
the spinal level. However, whether a genotype-dependent difference was seen depended 
upon the efficacy of the agonist and the strength of the noxious stimulus; a greater effect 
of the Gαo +/- genotype was manifested in the presence of the partial agonist nalbuphine 
or against a higher temperature stimulus. In contrast, there were no differences observed 
in the antinociceptive response to morphine in mice that were null for either Gαi2 or Gαi3, 
compared with their respective wild type littermates, at either the supraspinal or the 
spinal level. Furthermore, the loss of Gαo protein in Gαo -/- mice resulted in a decrease in 
Gβ and Gγ expression, a reduction in the number of high-affinity  opioid receptor 
binding sites, and consequently, attenuation of  agonist-stimulated [
35
S]GTPγS binding. 
Together, these results provide strong evidence that  opioid receptor coupling to Gαo is 
important for opioid antinociception. 
 Agonist-mediated antinociception 
In wild type mice, there was no difference in the potency of morphine observed at 
the higher hot plate temperature of 55
o
C when compared with 52
o
C, and morphine 
remained fully effective at both temperatures. However, this effect of temperature was 
exaggerated in Gαo +/- mice such that a larger shift in the potency of morphine was 
realized at the higher hot plate temperature, and even at 100 mg/kg, full antinociception 
was not attained. This suggests a reduced efficiency of antinociceptive processing in the 




Figure 2.6: DAMGO- and morphine-stimulated G protein activity in spinal cord 
homogenates from Gαo transgenic mice. 
[
35
S]GTPγS (0.1 nM) incorporation stimulated by 10 M DAMGO or morphine was 
evaluated in membrane homogenates from spinal cord of wild type and Gαo +/- mice. 
Non-specific binding was evaluated in the presence of unlabeled GTPγS (10 M). Data 
are plotted as agonist-stimulated [
35
S]GTPγS binding, defined as the increase in 
[
35
S]GTPγS binding in the presence of agonist over that of basal (measured in the 
absence of agonist), and represent the mean ± SEM (n=3 performed in quadruplicate). 
Asterisks indicate a statistical difference versus wild type by Students’ paired t-test 
(*p<0.05, **p<0.01). Inset, representative Western blot in spinal cord membranes 
showing reduced Gαo protein expression in Gαo +/- mice (+/-) when compared with wild 
type (wt) controls; membranes were probed for tubulin as a loading control.
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In confirmation of this, methadone, which has higher efficacy than morphine (Adams et 
al., 1990; Peckham and Traynor, 2006; McPherson et al., 2010), showed a smaller 
genotype difference. These findings confirm a role for Gαo in opioid agonist-mediated 
supraspinal antinociception against a thermal stimulus, but also indicate that in the      
Gαo +/- mice, sufficient Gαo protein remains to give a robust response and/or that other 
Gαi/o proteins are involved in the response. However, this latter suggestion is less likely 
given the absence of a difference between Gαi2 or Gαi3 null mice and their wild type 
littermates and the lack of compensatory changes in the expression of other Gαi/o proteins 
in Gαo null mice. 
Surprisingly, in light of findings in the hot plate test, but in agreement with 
previous ODN studies (Raffa et al., 1994; Sanchez-Blazquez et al., 1995; Standifer et al., 
1996; Sanchez-Blazquez et al., 2001), there was not a genotype-dependent difference in 
the ability of systemic morphine to produce antinociception between wild type and      
Gαo +/- mice using the tail withdrawal test. However, there was a profound shift in the 
potency of the partial agonist nalbuphine, which has lower efficacy than morphine 
(Dykstra et al., 1997; Selley et al., 1998). This suggests, as with the hot plate test, that the 
relationship between the strength of the noxious stimulus and the efficacy of the ligand 
determines if a genotype difference is observed. These findings imply that blockade of 
spinal nociception, as measured in the tail withdrawal test, requires less agonist efficacy. 
As a result, even with a large reduction in Gαo protein, the system is still able to function 
efficiently. 
Previous studies have shown that ODN knockdown of Gα subunits inhibits 
antinociception in an agonist-specific manner, suggesting that different agonists may 
cause the  receptor to signal through different Gα proteins. For example, antinociception 
induced by the partial agonist buprenorphine in the warm-water tail withdrawal test was 
significantly reduced after administration of antisense ODNs targeting Gαi2, Gαi3, Gαo2, 
Gαz or Gαq, whereas morphine antinociception was only attenuated in the presence of 
ODNs targeting Gαi2 or Gαz (Sanchez-Blazquez et al., 2001). However, in our study, 
morphine antinociception in the tail withdrawal test was not altered upon loss of Gαo, 
Gαi2 or Gαi3. Our findings indicate this may be due to differences in relative agonist 
efficacy, which suggests that there is a Gαo protein reserve for full agonists such that 
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even a significant knockdown of Gαo does not necessarily alter the ability of morphine to 
elicit antinociception, whereas a partial agonist, such as nalbuphine, is more susceptible. 
Indeed, Standifer et al. (1996) reported a reduction in morphine antinociception in the 
radiant-heat tail flick assay in mice exhibiting >60% knockdown of Gαo. On the other 
hand, the reason(s) why knockdown of Gαi2 and other Gα subunits affected 
antinociception in a ligand-dependent manner in previous studies is not clear, but may be 
due to differences in the route of administration (central versus peripheral) or the 
approach used (ODN versus constitutive knockdown). For example, in our constitutive 
knockdown, although no compensatory changes in Gαi/o protein expression were 
observed, other developmental changes may have occurred to substitute for the loss of 
Gαo specifically. 
 Receptor-dependent G protein activation 
Loss of Gαo, as determined by Western blot, was accompanied by a reduction in 
both Gβ and Gγ subunits. Valenzuela et al. (1997) observed a similar decrease in Gβ 
protein in ventricular membranes from a separately generated Gαo -/- mouse. This 
reduction in Gβγ is likely due to the instability of these subunits in the absence of 
sufficient concentrations of Gα protein (Hwang et al., 2005). A mechanism of regulated 
Gα and Gβy expression would prevent the accumulation of free Gβy dimers that are 
functionally competent in the absence of receptor agonist (Jiang et al., 1998). Reductions 
in free Gβ and Gγ levels were not observed in brains from mice lacking either Gαi2 or 
Gαi3 (data not shown), presumably due to the lower expression levels of these Gα 
proteins. 
This decrease in Gαo and accompanying Gβ and Gγ subunits, in addition to 
reducing the antinociceptive response, also reduced the ability of  agonists to stimulate 
[
35
S]GTPγS incorporation in whole brain or spinal cord homogenates. Indeed, DAMGO- 
and morphine-stimulated binding of 0.1 nM [
35
S]GTPγS were abolished in whole brain 
homogenates from Gαo -/- mice, confirming the importance of Gαo for  opioid receptor 
signaling (Jiang et al., 1998; Jiang et al., 2001). The reduction in Gαo and cognate Gβ and 
Gγ subunits also resulted in a decrease in high-affinity  receptor binding sites, but not 
total  receptor sites, suggesting a reduction in heterotrimeric G protein coupling. 
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However, high-affinity  opioid receptor binding was still present in the complete 
absence of Gαo, which could indicate that other Gαi/o subunits are taking the place of Gαo 
and providing a functional compensation, even though there were no obvious increases in 
the levels of these isoforms. Indeed, analysis of DAMGO-stimulated [
35
S]GTPγS 
saturation binding revealed a Gα protein to high-affinity  receptor ratio (Gα: receptor) 
of approximately 34:1 in wild type mice, compared with 24:1 in Gαo +/- mice and 10:1 in 
Gαo -/- mice. These results suggest that, in the brain, Gα proteins other than Gαo are able 
to form complexes with  opioid receptors. Such complexes might also help to 
translocate  receptors to the cell surface, as with  opioid receptor/Gαi2 complexes that 
are preassembled in secretory vesicles before delivery to the plasma membrane (Zhao et 
al.). However, G protein was not required for  opioid receptor translocation; if this was 
also true for  receptors, it would explain the high level of low-affinity  opioid receptors 
present in the Gαo -/- mice. 
 In spinal cord homogenates, both total and high-affinity  opioid receptor 
numbers are considerably less than in whole brain of wild type mice. Furthermore, there 
was no change in  receptor expression observed in spinal cord tissue from Gαo +/- mice. 
This could be because of an overabundance of Gαo compared with  opioid receptors in 
the spinal cord. It is unlikely that other Gα subunits are making a bigger contribution in 
the spinal cord given that there is no difference in morphine antinociception in the tail 
withdrawal test between Gαi2 or Gαi3 null mice and their wild type littermates. Similarly, 
differences between supraspinal and spinal antinociceptive circuitry have been 
demonstrated in a Gαz-deficient mouse (Hendry et al., 2000), although the mechanisms 
underlying these supraspinal versus spinal differences were not further characterized. 
Together, these findings suggest that  opioid receptor signaling in the spinal cord may 
be more efficient, such that full behavioral responses can be achieved at much lower  
receptor expression and/or upon activation of a smaller fraction of the total pool of G 
proteins. 
Concluding remarks 
The present results using Gαo +/- mice demonstrate that Gαo plays an important 
role in opioid antinociception. Moreover, changes observed in opioid antinociception in 
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Gαo +/- mice were paralleled by similar alterations in opioid-dependent signaling at the 
cellular level. This conclusion is further supported by the recent work of Kest et al. 
(2009), who showed that Gαo expression modulates opioid dependence by targeted 
knockdown in mice of Gαo mRNA, which reduced the expression of withdrawal after 
chronic heroin or morphine. However, despite the strong evidence linking Gαo to opioid 
antinociception, these findings cannot be taken as absolute proof that  opioid receptor 
coupling to Gαo is required for morphine analgesia. Gαo is important for the signaling and 
activity of many neurotransmitter receptors in the central nervous system (reviewed in 
Jiang and Bajpayee, 2009). Thus, it is possible that non-opioid pathways are 
compromised in the Gαo +/- mice and contribute to the altered antinociceptive responses 
(Connor and Christie, 1999). These and other questions related to the consequences of 
regional knockdown of Gαo will be addressed in future studies. Nevertheless, the finding 
that in addition to antinociception, both high-affinity  receptor expression and  agonist-
stimulated G protein activity are reduced strongly supports the notion that the Gαo- 
receptor complex plays a key role in opioid antinociception.
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Chapter 3  
Differential Control of Opioid Antinociception to Thermal Stimuli in a Knock-In 
Mouse Expressing RGS-Insensitive Go Protein 
Summary 
RGS proteins classically function as negative modulators of GPCR signaling. In 
vitro, RGS proteins have been shown to inhibit signaling by agonists at the  opioid 
receptor, including morphine. The goal of the present study was to evaluate the 
contribution of endogenous RGS proteins to the antinociceptive effects of morphine and 
other opioid agonists. To do this, a knock-in mouse that expresses an RGSi mutant Go 
protein, Go
G184S
 (Go RGSi), was evaluated for morphine or methadone antinociception 
in response to noxious thermal stimuli. Mice expressing Go RGSi subunits exhibited a 
naltrexone-sensitive enhancement of baseline nociception in both the hot plate and warm-
water tail withdrawal tests. In the hot plate test, a measure of supraspinal nociception, 
morphine antinociception was increased, and this was associated with an increased ability 
of opioids to inhibit presynaptic GABA neurotransmission in the PAG. In contrast, 
antinociception produced by either morphine or methadone was reduced in the tail 
withdrawal test, a measure of spinal nociception. In whole brain and spinal cord 
homogenates from mice expressing Go RGSi subunits, there was a small loss of Go 
expression and an accompanying decrease in basal G protein activity. Overall, this work 
strongly supports a role for RGS proteins as negative regulators of opioid supraspinal 
antinociception. Further, these studies also reveal a potential novel function of RGS 
proteins as positive regulators of opioid spinal antinociceptive pathways. 
Introduction 
Morphine produces analgesia by activating the  opioid receptor, a member of the 
GPCR superfamily.  Opioid receptor stimulation results in the activation of 
heterotrimeric Gi/o proteins composed of a Gi/o subunit and a G heterodimer. 
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Signaling is terminated via the intrinsic GTPase activity of the Gi/o subunit, and this 
process is enhanced by RGS proteins. RGS proteins are GAPs and therefore reduce Gi/o-
mediated signaling duration and intensity (De Vries et al., 2000; Ross and Wilkie, 2000; 
Hollinger and Hepler, 2002). Consequently, RGS proteins have been proposed as drug 
targets for several disease states, including both pain and addiction (Neubig and 
Siderovski, 2002; Traynor and Neubig, 2005).  
There are 20 RGS proteins with GAP activity. These are divided into several 
families based on the structure of the RH domain that binds G and is responsible for the 
classical GAP function (Figure 1.4). RGS proteins have been demonstrated to negatively 
regulate signaling through several GPCRs in vitro, including  opioid receptors (Potenza 
et al., 1999; Clark et al., 2003; Clark and Traynor, 2004; Psifogeorgou et al., 2007). 
Studies evaluating the contribution of individual RGS proteins to opioid effects in vivo 
have generally utilized knockdown or gene knockout strategies in mice (for examples, 
see Garzon et al., 2003; Zachariou et al., 2003b; Garzon et al., 2004; Garzon et al., 2005; 
Grillet et al., 2005; Han et al., 2010). However, the phenotypic effect(s) of eliminating a 
single RGS protein are often reported to be quite small (Grillet et al., 2005), which could 
be due to developmental compensations and/or redundancy within the RGS family.  
The aim of the present study was to test the hypothesis that endogenous RGS 
proteins negatively regulate opioid antinociception via interaction with Go subunits 
using a novel knock-in mouse that expresses the Go RGSi subunits (Goldenstein et al., 
2009). The relationship between RGS proteins and Go is of particular interest in light of 
our previous work demonstrating that Go plays a significant role in opioid 
antinociception (Lamberts et al., 2011; see also Chapter 2 of this thesis). For these 
studies, Go RGSi heterozygous knock-in mice (Go +/GS) were compared with wild 
type littermates, as homozygous knock-in mice (Go GS/GS) are not viable (Goldenstein 
et al., 2009; Kehrl et al., 2012). Morphine or methadone antinociception was evaluated in 
Go +/GS mice using two different noxious thermal stimuli: the hot plate test for 
supraspinal nociception and the warm-water tail withdrawal test for spinal nociception. In 
addition, opioid modulation of GABA synaptic transmission was monitored in PAG 
neurons. Loss of RGS activity toward Go resulted in prolonged baseline latencies in 
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both nociceptive tests due to an enhancement of endogenous opioid peptide signaling. 
Moreover, there was an enhanced potency of morphine to elicit antinociception in the hot 
plate test and to inhibit GABAergic transmission in the PAG in Go +/GS mice, all 
pointing to negative regulation of  opioid receptor signaling by RGS proteins. In 




Knock-in mice expressing Go RGSi subunits were generated as previously 
described (Fu et al., 2004; Fu et al., 2006; Huang et al., 2006; Goldenstein et al., 2009) 
and were maintained for 6 generations on a 129S1/SvImJ (129S1) background. Go +/GS 
and wild type littermates were obtained at the expected Mendelian frequency for wild 
type and Go +/GS crosses (data not shown). Experiments were performed using male 
and female mice aged 10 – 25 weeks and weighing 20 – 25 g. Mice were group-housed 
by sex with unlimited access to food and water. Lights were maintained on a 12-h 
light/dark cycle (lights on at 7:00), and all testing was performed during the light phase. 
Studies were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals established by the National Institutes of Health and all experimental protocols 
were approved by the University of Michigan Committee on the Use and Care of 
Animals. 
Antinociceptive tests 
Supraspinal antinociception was evaluated in the hot plate test and spinal 
antinociception was measured in the warm-water tail withdrawal assay using a 
cumulative dosing procedure as previously described (Lamberts et al., 2011). Briefly, 
mice were administered saline followed by 3-4 increasing doses of morphine or 
methadone in 30 min intervals, and latency was evaluated 30 min following each 
injection (i.p.). To evaluate the role of endogenous opioid peptides in baseline 
nociception, latency was determined 30 min after the injection of the opioid antagonist 
naltrexone (10 mg/kg, i.p.). 
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For the hot plate test, mice were placed on a hot plate analgesia meter (Columbus 
Instruments, Columbus, OH) maintained at 52.0 ± 0.2
o
C and the latency to lick 
forepaw(s) or jump was measured with a cutoff time of 60 s to prevent tissue damage. 
For the tail withdrawal test, mice were lightly restrained and the distal tip of the mouse’s 
tail was placed in a water bath (Fisher Scientific, Waltham, MA) maintained at 50.0 ± 
0.5
o
C. The latency to tail flick was measured with a cutoff time of 20 s. 
Membrane preparation 
Mice were killed by cervical dislocation and whole brain tissue (minus 
cerebellum) or thoracic and lumbar spinal cord was removed and immediately chilled in 
ice-cold 50 mM Tris, pH 7.4 (Tris buffer). Homogenates were prepared as previously 
described (Lester and Traynor, 2006) and final membrane pellets were resuspended in 
Tris buffer and stored at -80
o
C until use, unless otherwise indicated. Protein content was 
determined by the method of Bradford (Bradford, 1976). 
Western blot analysis of G proteins 
Whole brain or spinal cord homogenates (20 g protein) were mixed with sample 
buffer (63 mM Tris, pH 6.8, with 2% SDS, 10% glycerol, 0.008% bromophenol blue and 
50 mM dithiothreitol) and separated by SDS-PAGE on polyacrylamide gels. Proteins 
were transferred to nitrocellulose (Pierce, Rockford, IL) and probed with rabbit 
polyclonal anti-Go (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA). Samples were 
also probed with mouse monoclonal anti--tubulin (1:1000; Sigma-Aldrich, St. Louis, 
MO) as a loading control. Blots were then incubated with horseradish peroxidase-
conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:10,000) and 
immunoreactivity was detected by enhanced chemiluminesence in an EpiChem3 
Benchtop Darkroom (UVP, Upland, CA). Band densities were quantified using Image J 
software (http://rsbweb.nih.gov/ij/index.html). 
Receptor binding assays 
To evaluate total opioid receptor and total  receptor expression, homogenates 
from whole brain (100 g protein) or spinal cord (100-200 g protein, freshly prepared) 
were incubated in Tris buffer with the radiolabeled opioid antagonist [
3
H]diprenorphine 
(4 nM) in the absence or presence the -selective antagonist CTAP (300 nM) to define  
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opioid receptors. To measure high-affinity  receptor expression, homogenates from 
whole brain (100 g protein) were incubated in Tris buffer with increasing concentrations 
of the radiolabeled -selective agonist [
3
H]DAMGO (0.24 – 44 nM). Homogenates from 
spinal cord (100-200 g protein, freshly prepared) were incubated in Tris buffer with 12 
nM [
3
H]DAMGO. All binding reactions were incubated for 60 min at 25
o
C. Non-specific 
binding was evaluated in the presence of the opioid antagonist naloxone (10 M). 
Reactions were stopped by rapid filtration through GF/C filtermats (Whatman, Kent, UK) 
using a Brandel MLR-24 harvester (Brandel, Gaithersburg, MD). Bound radioactivity 
was determined by liquid scintillation counting using a Wallac 1450 MicroBeta counter 
(PerkinElmer, Waltham, MA). 
[
35
S]GTPγS binding assays 
To measure G protein activity, the incorporation of a slowly-hydrolyzed GTP 
analog, [
35
S]GTPS, into activated G subunits was monitored ex vivo. Homogenates 
from whole brain (10 g protein) or spinal cord (25-50 g protein, freshly prepared) were 
pre-incubated in [
35
S]GTPS binding buffer (50 mM Tris, 5 mM MgCl2, 100 mM NaCl 
and 1 mM EDTA, pH 7.4, with 2 mM dithiothreitol, 100 M GDP and 0.4 U/mL 
adenosine deaminase) for 10 min at 25
o
C with or without opioid agonist (DAMGO, 
morphine or methadone). Reactions were started by the addition of 0.1 nM [
35
S]GTPγS, 
followed by incubation for 90 min at 25
o
C. Non-specific binding was evaluated in the 
presence of 10 M unlabeled GTPS. Binding reactions were stopped by rapid filtration 
and bound radioactivity was measured by liquid scintillation counting, as above. 
Electrophysiology 
Mice were deeply anesthetized with isoflurane and brains were rapidly removed 
and placed in ice-cold cutting buffer (75 mM NaCl, 2.5 mM KCl, 0.1 mM CaCl2, 6 mM 
MgSO4, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.5 mM D-glucose and 50 mM sucrose). 
Coronal sections (~230 m) containing the PAG were sliced in cutting buffer oxygenated 
with 95% O2 and 5% CO2. Slices were then maintained at 35
o
C in oxygenated artificial 
cerebrospinal fluid (126 mM NaCl, 2.5 mM KCl, 2.4 mM CaCl2, 1.2 mM MgCl2, 1.2 




Whole-cell patch-clamp recordings were made from visually identified PAG 
neurons. Patch pipettes were pulled from borosilicate glass (WPI, Sarasota, FL) on a two-
stage puller (Narishige, Tokyo, JAPAN). Pipettes had a resistance of 2-4 M and 
intracellular solutions contained 130 mM CsCl, 5.4 mM KCl, 0.1 mM CaCl2, 2 mM 
MgCl2, 10 mM HEPES, 1.1 mM EGTA, 30 mM D-dextrose, 4 mM Mg-ATP and 1 mM 
Na-GTP, pH 7.3, at 280-290 mOsm. Whole-cell series resistance was compensated 
~80%. Evoked GABA-mediated inhibitory post-synaptic currents (eIPSCs) were elicited 
with a bipolar stimulating electrode placed ~200-300 mm distally from the recorded cell 
at a holding potential of -70 mV in the presence of the AMPA receptor antagonist NBQX 
(5 µM). Stimulation pulses (2 ms) were delivered at 0.05 Hz. Currents were collected at 2 
kHz and digitized at 5 kHz using an Axopatch 200B amplifier controlled by Axograph 
Data Acquisition software (Axograph X, Sydney, AUS). During each experiment, a 
voltage step of -10 mV from the holding potential was applied periodically to monitor 
cell capacitance and access resistance. Recordings in which access resistance or 
capacitance changed by >15% during the experiment were excluded from data analysis. 
Drugs 
For behavioral experiments, all drugs were diluted in sterile water. Morphine 
sulfate was from RTI (Research Triangle Park, NC), Naltrexone hydrochloride was from 
Endo Pharmaceuticals (Newark, DE), and L-methadone hydrochloride was from Eli Lilly 







purchased from PerkinElmer. Adenosine deaminase was obtained from Calbiochem (San 
Diego, CA). DAMGO, CTAP, naloxone, ME, and all other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO), unless otherwise noted. 
Data analysis 
All data were analyzed using GraphPad Prism 5 (San Diego, CA). Differences 
between genotypes were evaluated using Students’ unpaired t-test or two-way ANOVA 
with Bonferroni’s post-tests, where appropriate. For all statistical tests, significance was 
set at p<0.05 and was adjusted for multiple comparisons if necessary. Initial statistical 
analysis revealed a lack of sex × genotype interaction for any measure, so data from both 
male and female mice were pooled for final genotype comparisons. ED50 was calculated 
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by fitting the compiled antinociception data to an agonist versus response curve (Hill 
slope=1), Bmax and KD were derived by fitting each radioligand binding experiment to a 
one-site saturation binding curve (Hill slope=1), and EC50 was calculated by fitting 
individual [
35
S]GTPS binding experiments to an agonist versus response curve (Hill 
slope=1). All data are reported as the mean ± SEM, except ED50 values which are 
expressed as the mean (95% CI). 
Results 
Go +/GS mice demonstrate enhanced morphine antinociception in the hot plate test 
Go has previously been shown to play an important role in opioid 
antinociception (Lamberts et al., 2011). To determine whether antinociception mediated 
by Go is modulated by interactions with RGS proteins, Go +/GS mice were evaluated 
for opioid supraspinal antinociception using the 52
o
C hot plate test (Figure 3.1). In the 
absence of agonist, baseline hot plate latency was significantly prolonged in Go +/GS 
mice, when compared with wild type controls (p<0.01; Figure 3.1a). To evaluate whether 
the increase in baseline hot plate latency was due to enhanced opioidergic tone, a separate 
group of mice was pre-treated with the opioid antagonist naltrexone (10 mg/kg, i.p.) prior 
to determination of hot plate latency (Figure 3.1a). Pre-treatment with naltrexone blocked 
the increase in baseline hot plate latency in Go +/GS mice (p<0.01) but had no effect in 
wild type controls (p>0.05). Two-way ANOVA revealed significant effects of both 
genotype (F(1,66)=5.8, p=0.019) and treatment (F(1,66)=8.4, p=0.005), with a non-
significant genotype × treatment interaction (F(1,66)=2.9, p=0.094).  
Morphine evoked a dose-dependent increase in hot plate latency that was 
significantly enhanced (~2-fold) in Go +/GS mice, when compared with wild type 
controls (Figure 3.1b). In wild type mice, the potency (ED50) of morphine was 2.71 (2.10 
– 3.49) mg/kg compared with 1.46 (1.11 – 1.93) mg/kg in Go +/GS mice. There were 
significant effects of both dose (F(4,71)=79, p<0.001) and genotype (F(1,71)=7.7, 





Figure 3.1: Baseline nociception and opioid antinociception in the 52
o
C hot plate test 
in wild type and Go +/GS mice. 
 (a) Baseline hot plate latency was evaluated 30 min following saline (wild type, n=24; 
Go +/GS, n=18) or naltrexone (NTX; wild type, n=15; Go +/GS, n=13). **p<0.01 
compared with saline-treated wild type mice, 
##
p<0.01 compared with saline-treated   
Go +/GS mice by Bonferroni’s post-test. (b,c) Opioid supraspinal antinociception was 
evaluated as hot plate latency 30 min following increasing cumulative doses of (b) 
morphine (wild type, n=6-11; Go +/GS, n=6-9) or (c) methadone (wild type, n=12;   
Go +/GS, n=9). *p<0.05 compared with wild type mice at the corresponding dose by 
Bonferroni’s post-test. Legend in panel (b) also describes panel (c). Dotted lines indicate 
the test cutoff time. All data are plotted as the mean ± SEM.
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In contrast, there was no change in the antinociception produced by methadone in 
Go +/GS mice, when compared with wild type littermates (Figure 3.1c). The ED50 
values for methadone were 1.41 (1.01 – 1.96) mg/kg and 1.24 (0.91 – 1.69) mg/kg for 
wild type and Go +/GS mice, respectively. Statistical analysis revealed a significant 
effect of dose (F(2,57)=74, p<0.001), but neither a significant effect of genotype 
(F(1,57)=0.27, p=0.608) nor a significant dose × genotype interaction (F(2,57)=0.18, 
p=0.839). 
Opioid antinociception is reduced in Go +/GS mice in the tail withdrawal test 
To evaluate whether the enhancement of morphine antinociception in Go +/GS 
mice was specific to supraspinal pathways, antinociception was also evaluated in the 
50
o
C warm-water tail withdrawal test (Figure 3.2). The tail withdrawal test is thought to 
measure primarily spinal nociception and involves modulation of a simple spinal reflex 
(Irwin et al., 1951). At baseline, tail flick latency was slightly prolonged in Go +/GS 
mice, when compared with wild type littermates (p<0.05; Figure 3.2a). Similar to 
observations in the hot plate test, pre-treatment with naltrexone (10 mg/kg, i.p.) reversed 
the increase in tail flick latency in Go +/GS mice (p<0.05), but did not affect tail flick 
latency in wild type animals (p>0.05; Figure 3.2a). There was a significant genotype × 
treatment interaction (F(1,77)=5.2, p=0.026), although the main effects of either genotype 
(F(1,77)=0.63, p=0.428) or treatment (F(1,77)=1.4, p=0.236) were not significant.  
Increasing doses of morphine produced an increase in tail flick latency that was 
significantly reduced (~3-fold) in Go +/GS mice compared with wild type littermates 
(Figure 3.2b), with ED50 values of 3.08 (2.49 – 3.82) mg/kg and 1.11 (0.92 – 1.33) 
mg/kg, respectively. There were significant effects of both dose (F(3,76)=180, p<0.001) 
and genotype (F(1,76)=66, p<0.001), as well as a significant dose × genotype interaction 
(F(3,76)=10, p<0.001).  
Like morphine, methadone was also less potent (~2-fold) in in Go +/GS mice, 
when compared with wild type controls (Figure 3.2c), with ED50 values of 0.27 (0.22 – 
0.34) mg/kg and 0.12 (0.09 – 0.15) mg/kg, respectively. There were significant effects of 
both dose (F(3,78)=77, p<0.001) and genotype (F(1,78)=23, p<0.001), as well as a 




Figure 3.2: Baseline nociception and opioid antinociception in the 50
o
C warm water 
tail withdrawal test in wild type and Go +/GS mice. 
 (a) Baseline tail flick latency was evaluated 30 min following saline (wild type, n=21; 
Go +/GS, n=24) or naltrexone (NTX; wild type, n=23; Go +/GS, n=13). *p<0.05 
compared with saline-treated wild type mice, 
#
p<0.05 compared with saline-treated     
Go +/GS mice by Bonferroni’s post-test. (b,c) Opioid spinal antinociception was 
evaluated as tail flick latency 30 min following increasing doses of (b) morphine (wild 
type, n=11; Go +/GS, n=10) or (c) methadone (wild type, n=6-10; Go +/GS, n=8-14). 
*p<0.05, ***p<0.001 compared with wild type mice at the corresponding dose by 
Bonferroni’s post-test. Legend in panel (b) also describes panel (c). Dotted lines indicate 
the test cutoff time. All data are plotted as the mean ± SEM.
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Opioid inhibition of GABAergic transmission is potentiated in PAG neurons from Go 
+/GS mice 
One of the mechanisms by which opioids produce antinociception is by removing 
tonic GABA inhibition (i.e. by GABA disinhibition) of descending antinociceptive 
neurons that emanate from the PAG (Moreau and Fields, 1986; Reichling et al., 1988). 
This effect can be measured by evaluating the ability of opioids to inhibit electrically-
evoked GABAergic eIPSCs in slices containing the PAG (Vaughan and Christie, 1997; 
Vaughan et al., 1997). To determine the role of RGS proteins in opioid-mediated GABA 
disinhibition, slices containing the PAG were isolated from wild type and Go +/GS mice 
and the ability of either morphine or ME to inhibit eIPSCs was measured using whole-
cell voltage-clamp electrophysiology (Figure 3.3). 
Superfusion of morphine inhibited the amplitude of GABA eIPSCs in both wild 
type and Go +/GS mice, but the inhibition elicited by a submaximal concentration of 
morphine (5 M) was enhanced in slices from Go +/GS mice (p<0.05; Figure 3.3a). 
There were significant main effects of both concentration (F(1,18)=16, p<0.001) and 
genotype (F(1,18)=11, p=0.003), although the concentration × genotype interaction was 
not significant (F(1,18)=0.82, p=0.377). Similarly, application of ME at a concentration 
of either 300 nM or 10 M resulted in a greater inhibition of eIPSCs in slices from     
Go +/GS mice (p<0.05), when compared with slices from wild type littermates (Figure 
3.3b). There were significant effects of both concentration (F(1,8)=36, p<0.001) and 
genotype (F(1,8)=21, p=0.002), while the concentration × genotype interaction was not 
significant (F(1,8)=0.00, p=0.989). 
Go +/GS mice exhibit a loss of Go expression in brain and spinal cord 
To determine whether the knock-in mutation affected G protein levels, whole 
brain or spinal cord homogenates from Go +/GS mice were subjected to Western blot 
analysis of G protein expression (Figure 3.4). Quantification of Western blot images 
revealed that in Go +/GS mice, total Go protein expression was significantly reduced 
(~25-35%) in both whole brain (t(14)=2.2, p=0.048; Figure 3.4a) and spinal cord 




Figure 3.3: Opioid inhibition of GABA-mediated eIPSCs in slices containing the 
PAG from wild type (WT) and Go +/GS (+/GS) mice. 
Inhibition of GABA eIPSCs by either (a) morphine (n=5-6) or (b) ME (n=3) is shown as 
averaged traces before and after application of naloxone (NAL, 1 M; left) and as 
compiled % inhibition of GABA eIPSC amplitude (right). *p<0.05 compared with wild 




Figure 3.4: Go protein expression in whole brain or spinal cord homogenates from 
wild type (WT) and Go +/GS (+/GS) mice. 
Homogenates from (a) whole brain (n=8) or (b) spinal cord (n=7) were separated by 
SDS-PAGE, transferred to nitrocellulose, and probed for the expression of Go using 
tubulin as a loading control. Go band densities were quantified in Image J, normalized 
to tubulin band densities, and data are plotted as a percent of WT (mean ± SEM). 
*p<0.05 compared with wild type by Students’ t-test.
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In contrast, the expression of several other G protein subunits, including Gz, Gi1, Gi2, 
Gi3, G and G, was unchanged in either whole brain or spinal cord from Go +/GS 
mice (data not shown). 
It was previously demonstrated that loss of Go protein in mice results in reduced 
high-affinity  opioid receptor expression, with no change in total  receptor number 
(Lamberts et al., 2011). To evaluate whether the reduction in Go expression in          
Go +/GS mice affected high-affinity  receptor levels, whole brain or spinal cord 
homogenates were subjected to radioligand binding analysis using the -selective agonist 
[
3
H]DAMGO (Table 3.1). In homogenates from whole brain, saturation binding 
experiments revealed no difference in maximal [
3
H]DAMGO binding (Bmax) between 
genotypes (t(11)=0.73, p=0.479; Table 3.1). Furthermore, there were no differences in 
[
3
H]DAMGO binding affinity (KD) between Go +/GS mice and wild type controls 
(t(11)=0.54, p=0.600; Table 3.1). Similarly, there were no changes in high-affinity  
opioid receptor expression in spinal cord homogenates from Go +/GS mice, as measured 
by [
3
H]DAMGO binding at a maximal concentration (12 nM; t(6)=0.43, p=0.683; Table 
3.1). Total opioid receptor expression (,  and  opioid receptors), as measured by the 
non-selective antagonist [
3
H]diprenorphine (4 nM), was not different in either whole 
brain (t(9)=0.57, p=0.582) or spinal cord (t(6)=0.56, p=0.596) of Go +/GS mice 
compared with wild type littermates (Table 3.1).  Receptor expression was isolated from 
the total pool of opioid receptors using the -selective antagonist CTAP (300 nM). 
Neither whole brain (t(9)=0.56, p=0.590) nor spinal cord expression of  receptors 
(t(6)=0.73, p=0.495) was altered in Go +/GS mice, in comparison with wild type 
controls (Table 3.1). 
To determine whether the loss of Go protein in Go +/GS mice was associated 
with a reduction in G protein activation, opioid agonist-stimulated G protein activity was 
evaluated in whole brain or spinal cord homogenates using the [
35
S]GTPS binding assay 
(Figure 3.5, Table 3.2). In whole brain, basal [
35
S]GTPS binding was significantly lower 
in Go +/GS mice, when compared with wild type littermates (t(17)=3.5, p=0.003; Table 
3.2). However, [
35
S]GTPS incorporation stimulated by the -selective agonist DAMGO 
was unchanged in whole brain from Go +/GS mice (Figure 3.5a, top).
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Table 3.1: Agonist and antagonist radioligand binding in whole brain or spinal cord 


















Wild type 219 ± 23 3.3 ± 0.3 357 ± 56 190 ± 33 
Go +/GS 198 ± 18
 
3.0 ± 0.5 312 ± 56 166 ± 29 
Spinal 
cord 




Go +/GS 109 ± 22 ND 202 ± 24 116 ± 19 
 
ND, not determined.  Opioid receptor expression was measured by evaluating the 
amount of bound [
3
H]diprenorphine displaced by the -selective antagonist CTAP (300 
nM). Data represent the mean ± SEM (Whole brain: n=5-7; Spinal cord: n=4). Each 




Figure 3.5: Agonist-stimulated G protein activity in whole brain or spinal cord 
homogenates from wild type and Go +/GS mice. 
 [
35
S]GTPS binding was measured in (a) whole brain (n=8-9) and (b) spinal cord (n=3) 
in the presence of increasing concentrations of DAMGO (top) or morphine (bottom). 
*p<0.05 compared with wild type mice at the corresponding concentration by 
Bonferroni’s post-test. Legend in top panel also describes bottom panel. For all 
experiments, non-specific binding was determined using 10 M GTPS. Agonist-
stimulated [
35
S]GTPγS binding is shown as % stimulation, where % stimulation = [(Drug 
binding – Basal binding) / Basal binding] × 100. All data are plotted as the mean ± SEM.
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Table 3.2: Basal and agonist-stimulated [
35
S]GTPS binding in membranes from 

















Wild type 65.9 ± 2.2 524 ± 39 806 ± 210 
Go +/GS 46.5 ± 4.9** 722 ± 116 526 ± 98 
Spinal cord 
Wild type 66.8 ± 7.6 547 ± 103 174 ± 88 
Go +/GS 45.3 ± 4.6* 524 ± 121 332 ± 113 
 
*p<0.05 compared with wild type spinal cord, **p<0.01 compared with wild type whole 
brain by Students’ t-test. Data represent the mean ± SEM (Whole brain: n=8-9, Basal 
n=10; Spinal cord: n=3, Basal n=5). Each sample was assayed in duplicate.
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Statistical analysis of DAMGO concentration-response curves obtained in whole brain 
homogenates from wild type and Go +/GS mice revealed a significant effect of 
concentration (F(7,128)=53, p<0.001), while there was neither a significant effect of 
genotype (F(1,128)=0.45, p=0.503) nor a significant concentration × genotype interaction 
(F(7,128)=0.22, p=0.980). There was also no change in DAMGO potency (EC50) 
between Go +/GS mice and wild type littermates (t(16)=1.6, p=0.126; Table 3.2). In 
contrast, morphine-stimulated G protein activation was attenuated in whole brain 
homogenates from Go +/GS mice compared with wild type controls (Figure 3.5a, 
bottom). Analysis of the morphine concentration-response in whole brain homogenates 
from wild type and Go +/GS mice demonstrated significant effects of both concentration 
(F(7,112)=36, p<0.001) and genotype (F(1,112)=6.6, p=0.012), although the 
concentration × genotype interaction was not significant (F(7,112)=0.92, p=0.493). 
However, there was no difference in the EC50 for morphine between Go +/GS and wild 
type mice (t(14)=1.2, p=0.247; Table 3.2). G protein activation was also measured in 
whole brain homogenates using a saturating concentration of methadone (10 M). 
[
35
S]GTPS incorporation stimulated by methadone was unchanged in whole brain from 
Go +/GS mice (% stim: 64.2 ± 11, n=4), when compared with wild type controls (% 
stim: 69.0 ± 15 fmol/mg, n=3; t(5)=0.27, p=0.801). 
In the spinal cord, there was also a reduction in basal [
35
S]GTPS incorporation in 
Go +/GS mice (t(8)=2.4, p=0.042; Table 3.2). DAMGO stimulation of G protein 
activation was not different between wild type and Go +/GS spinal cord (Figure 3.5b, 
top). There was a significant main effect of concentration (F(7,32)=88, p<0.001), 
although the effect of genotype (F(1,32)=0.25, p=0.623), and the concentration × 
genotype interaction were not significant (F(7,32)=0.08, p=0.999). Moreover, there was 
no difference in DAMGO EC50 between genotypes in this tissue (t(4)=0.14, p=0.892; 
Table 3.2). Morphine-stimulated G protein activity was also unchanged in spinal cord 
from Go +/GS mice in comparison with wild type littermates (Figure 3.5b, bottom). 
There was a significant effect of concentration (F(7,32)=21, p<0.001), while there was no 
significant effect of genotype (F(1,32)=0.37, p=0.545) and no significant concentration × 
genotype interaction (F(7,32)=0.72, p=0.658). Moreover, morphine EC50 was not altered 
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in spinal cord homogenates from Go +/GS mice as compared with wild type littermates 
(t(4)=1.1, p=0.332; Table 3.2). 
Discussion 
These studies show that endogenously-expressed RGS proteins regulate opioid 
antinociception by acting at Go. Mice expressing Go RGSi subunits demonstrated an 
opioid-dependent increase in baseline responsiveness to two different thermal stimuli: the 
hot plate test, a measure of supraspinal nociception (Heinricher and Morgan, 1999), and 
the warm-water tail withdrawal test, which primarily involves spinal nociceptive 
pathways (Irwin et al., 1951; Cesselin et al., 1999). Furthermore, these mice exhibited an 
enhancement of morphine-mediated antinociception in the hot plate test, as well as a 
potentiation of morphine or ME inhibition of presynaptic GABA transmission in the 
PAG. Together, these data confirm the hypothesis that RGS proteins negatively regulate 
 opioid receptor signaling and antinociception. In contrast, there was no effect of the 
loss of RGS regulation on methadone antinociception in the hot plate test and an 
unexpected reduction in morphine and methadone antinociception in the tail withdrawal 
test. Overall, the results demonstrate that although RGS proteins negatively regulate  
opioid receptor signaling in vivo, they differentially alter opioid-mediated antinociception 
depending upon the agonist and nociceptive pathway(s) involved. 
Pretreatment of wild type mice with naltrexone did not affect baseline latency in 
either the hot plate or the tail withdrawal test, indicating that endogenous opioid peptide 
tone is insufficient to cause an antinociceptive response. In contrast, Go +/GS mice 
exhibited a naltrexone-sensitive increase in baseline latency in both the hot plate and tail 
withdrawal tests, compared with their wild-type littermates. This is likely due to 
enhanced  receptor signaling in response to endogenous opioid peptides only in mice 
expressing Go RGSi subunits.  
Removal of negative regulation of Go by RGS proteins also resulted in enhanced 
morphine-mediated antinociception in the hot plate test, indicating that RGS proteins 
function as negative regulators of morphine supraspinal antinociception. In support of 
this, and in line with the role of RGS proteins as negative regulators of signaling, there 
was a robust potentiation of opioid (morphine or ME) inhibition of GABAergic 
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neurotransmission in PAG from Go +/GS mice. The ability of opioids to inhibit 
presynaptic GABA neurotransmission in the PAG is thought to underlie the production of 
antinociception (Moreau and Fields, 1986; Reichling et al., 1988).   
In contrast to the hot plate test, morphine antinociception as measured in the tail 
withdrawal test was significantly reduced in Go +/GS mice. Although a reduction in 
Go protein was observed in the spinal cord, it is unlikely that Go levels are a limiting 
factor for morphine spinal antinociception, given that a >50% loss of Go protein did not 
affect morphine antinociception in the tail withdrawal test (Lamberts et al., 2011). Thus, 
it appears that the reduction in morphine spinal antinociception in Go +/GS mice is a 
direct consequence of the inability of Go RGSi subunits to bind RGS proteins, indicating 
that RGS proteins act as positive regulators of opioid antinociception in this test. The 
reasons for this are not immediately obvious given that there was a naltrexone-sensitive 
increase in baseline nociception in Go +/GS mice, which implicates negative regulation 
of endogenous opioid peptide signaling by RGS proteins that was confirmed by the 
electrophysiological measurements in the PAG. On the other hand, a contribution from 
altered endogenous opioid peptide release in Go +/GS mice cannot be discounted. 
Another possible explanation is that the endogenous enkephalins are discretely 
released at specific synapses, whereas the systemically-administered morphine acts at 
many spinal and supraspinal sites and so may recruit opposing transmitter systems that 
are also subject to regulation by RGS proteins. Alternatively,  opioid receptor function 
may be differentially regulated by RGS proteins in diverse neuronal systems due to 
variations in the  receptor environment, for example the presence of particular accessory 
and/or scaffolding proteins may lead to differential regulation between spatially or 
temporally distinct signaling pathways such that they enhance some responses while 
simultaneously inhibiting others (Clark et al., 2003; Zhong et al., 2003). In any case, our 
findings in Go +/GS mice are reminiscent of observations made in RGS9 knockout 
mice, in which morphine supraspinal antinociception was enhanced (Zachariou et al., 
2003b), while morphine spinal antinociception was reduced (Papachatzaki et al., 2011). 
These authors showed that RGS9 was required for the opioid peptide DAMGO to cause 
hyperpolarization in lamina II dorsal horn neurons, and therefore they suggest that  
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RGS9-2 performs a scaffolding role. However, our results in Go +/GS mice indicate that 
loss of RGS GAP activity alone is sufficient to observe this phenomenon. The reason for 
the difference in responses between endogenous opioid peptides and morphine in the tail 
withdrawal test could then be explained by a predominantly central site (i.e. PAG) for 
opioid peptide action and a predominantly spinal action of systemically-administered 
morphine.  
There were also agonist-specific differences in the two antinociceptive tests. In 
the hot plate test, methadone did not produce different responses between Go +/GS mice 
and their wild type littermates. In contrast, in the tail withdrawal test methadone 
antinociception was shifted to a lower potency, although the effect was less than that seen 
with morphine. There are other reports that RGS proteins can act as either positive or 
negative regulators of opioid antinociception, depending upon the agonist tested. For 
example, knockout of RGS9 has been shown to enhance morphine antinociception but 
inhibit methadone or fentanyl antinociception in the hot plate test (Psifogeorgou et al., 
2011), while in the tail withdrawal test knockout of RGS4 did not alter morphine-
mediated antinociception but did inhibit fentanyl and methadone antinociception (Han et 
al., 2010). At least for RGS9-2, this effect has been ascribed to the formation of 
complexes containing RGS9-2 and  opioid receptors in association with different G 
subunits, depending on the  agonist. However, our current results suggest that GAP 
activity alone might be responsible for the agonist-specific results. In particular, the 
differences observed between morphine and fentanyl or methadone could be attributed to 
the higher efficacy of the latter compounds, as compared with morphine (Adams et al., 
1990; Peckham and Traynor, 2006; McPherson et al., 2010), since RGS proteins are 
much less effective in modulating full versus partial agonists (Clark et al., 2003; Clark et 
al., 2008).  
An important caveat to our findings is that mice expressing Go RGSi subunits 
exhibited baseline alterations in G protein expression and activity. Specifically, in whole 
brain and spinal cord homogenates from Go +/GS mice, there was a 25-35% decrease in 
total Go protein expression, which was consistent with the observed reduction in basal 
[
35
S]GTPS binding. This loss of Go protein is likely a compensatory response to the 
enhanced signaling activity of Go RGSi subunits. Alternatively, there may be altered 
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expression of the Go
 
RGSi mutant allele that contains a non-genomic insertion in exon 5 
of Gnao1 (Fu et al., 2004; Goldenstein et al., 2009). However, the reduction in Go 
protein in these mice was not sufficient to affect the expression of  opioid receptors in 
whole brain or spinal cord, and it had only a small effect on the maximum stimulation of 
[
35
S]GTPS by the partial agonist morphine in whole brain, but not spinal cord. Thus, the 
25-35% reduction in Go expression in Go +/GS mice is unlikely to contribute to the 
behavioral differences observed in this study. Indeed, the effects observed in the PAG 
and on the antinociceptive behavior of both morphine and endogenous opioid peptides 
are likely to be an underestimate of the degree of RGS modulation of  receptor-
mediated signaling and behavior, given that heterozygous mice have only one allele of 
Gnao1 that expresses Go RGSi. 
In conclusion, the current studies utilize a novel knock-in mouse model to 
demonstrate a role for RGS proteins in opioid antinociception mediated specifically by 
Go. The results demonstrate that endogenous RGS GAP activity negatively regulates (1) 
antinociceptive responses to endogenous enkephalins, (2) morphine antinociception in the 
hot plate test, and (3) opioid inhibition of GABAergic transmission in the PAG. In 
contrast, these studies revealed a potential role of RGS proteins as positive regulators of 
morphine and methadone antinociception in the tail withdrawal assay. Thus, the present 
work provides evidence that endogenous RGS proteins are able to differentially regulate 
diverse nociceptive and antinociceptive pathways that are activated by a single 
nociceptive modality. Although the importance of the interaction between RGS proteins 
and Go subunits for  opioid receptor function remains to be fully elucidated, this 
interface could represent a novel target for the development of more effective pain 
therapeutics and/or new treatments for drug addiction. For example, the fact that         
Go +/GS mice show reduced responsiveness to a noxious stimulus suggests that 
inhibition of RGS activity alone could afford an antinociceptive effect.
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  Chapter 4
Role of Go in Morphine Tolerance and Dependence: Studies in 129S6 Mice  
Summary 
Morphine is a powerful pain reliever, although the long-term use of morphine and 
other opioids is limited by the development of adaptations such as analgesic tolerance 
and physical dependence. Morphine produces its behavioral effects by activating the  
opioid receptor, which couples to inhibitory (Gi/o-containing) heterotrimeric G proteins. 
Recent evidence suggests that the antinociceptive effects of morphine in mice are 
mediated by Go. However, the role of Go in the development of morphine tolerance 
and dependence is currently not known. To evaluate the contribution of Go to 
adaptations associated with chronic morphine use, Go +/- mice were repeatedly 
administered morphine over a short (acute) or long (chronic) timescale and then 
examined for tolerance using the 52
o
C hot plate as the nociceptive stimulus and for 
dependence by evaluating the severity of opioid antagonist-precipitated withdrawal. Wild 
type littermates on the same genetic background as Go +/- mice (129S6) were evaluated 
in parallel as controls. Following either acute or chronic morphine treatment, all 129S6 
mice developed antinociceptive tolerance and physical dependence, regardless of 
genotype. However, Go +/- mice developed tolerance more rapidly and displayed more 
severe antagonist-precipitated withdrawal than did wild type littermates following 
chronic morphine treatment. Morphine tolerance was not associated with changes in  
opioid receptor function in brain homogenates from either wild type or Go +/- mice. 
Thus, Go protein appears to offer some protection against morphine tolerance and 
dependence. 
Introduction 
Morphine is an extremely effective analgesic drug. Unfortunately, chronic use of 
morphine and other opioids results in the development of behavioral adaptations such as 
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tolerance and dependence, which reduces the effectiveness of these drugs over the long-
term. In humans, morphine analgesic tolerance is characterized by a decrease in analgesic 
efficacy such that higher doses of morphine (in some cases more than 10-fold) are 
required for the continued therapeutic management of pain (Buntin-Mushock et al., 
2005). Further, repeated use of morphine results in physical dependence, which is 
characterized by an unpleasant, though non-life threatening withdrawal syndrome upon 
abrupt discontinuation of treatment (Farrell, 1994). Despite all that is known regarding 
morphine tolerance and dependence, the inherent complexity of these adaptations 
requires that they be further studied before better analgesic treatments that are devoid of 
such adaptations can be proposed. 
Morphine elicits the majority of its behavioral effects, including physical 
dependence, by activating the  opioid receptor (Matthes et al., 1996), a member of the 
GPCR superfamily of transmembrane receptors. GPCRs are characterized by their 
coupling to heterotrimeric G proteins composed of a G subunit bound to a G 
heterodimer. At the cellular level, acute stimulation of  receptors by morphine results in 
the activation of Gi/o-containing G proteins that inhibit the activity of AC enzymes, 
activate GIRK channels, inhibit Ca
2+
 channels, and stimulate MAPK phosphorylation, 
among other pathways (Law et al., 2000).  Receptor coupling to Gi/o proteins, and in 
particular Go, is important for the production of  agonist-mediated antinociception in 
mice (Lamberts et al., 2011).  
Chronic/continuous morphine exposure has been associated with the uncoupling 
of several  opioid receptor-dependent, Gi/o-mediated signaling pathways in both mice 
and rats (Eitan et al., 2003; Bagley et al., 2005a; Fyfe et al., 2010). This loss of  receptor 
signaling following chronic morphine treatment is thought to result from either a 
reduction in the expression of Gi/o subunits (Selley et al., 1997a; Yoburn et al., 2003) 
and/or a decrease in the interaction between  receptors and Gi/o proteins (Sim et al., 
1996; Elliott et al., 1997; Maher et al., 2001; Wang et al., 2005; Sim-Selley et al., 2007; 
Smith et al., 2007). 
On the other hand,  opioid receptor uncoupling from Gi/o proteins is not always 
observed following chronic morphine treatment (Contet et al., 2008; Madia et al., 2012), 
 
74 
and in fact several studies have reported that chronic morphine induces the upregulation 
of Gi/o protein expression in various brain regions (Nestler et al., 1989; Terwilliger et 
al., 1991; Fabian et al., 2002; Wang et al., 2004). There is also evidence of enhanced  
receptor-dependent signaling via Gi/o following chronic morphine treatment (Ingram et 
al., 2008). Moreover, both knockdown and overexpression of Gi2 have been shown to 
ameliorate morphine antinociceptive tolerance in mice (Sanchez-Blazquez and Garzon, 
1994; Garzon and Sanchez-Blazquez, 2001; Yoburn et al., 2003). Thus, although Gi/o 
activation represents a critical first step in the initiation of  opioid receptor signaling, the 
role of this early phase of  receptor activity in the adaptations associated with chronic 
morphine use remains controversial. 
It has recently been demonstrated that mice with a 50% reduction in Go protein 
(Go +/- mice) exhibit a significant decrease in morphine-mediated antinociception 
(Lamberts et al., 2011). Furthermore, it has been hypothesized that genetic variation in 
the expression level of the Go gene, Gnao1, determines the severity of morphine 
dependence (Kest et al., 2009). Here, to determine whether Go plays a role in the 
adaptations that accompany chronic morphine treatment, the development of morphine 
tolerance and dependence were evaluated in Go +/- mice alongside wild type 129S6 
littermates as controls. Furthermore, biochemical endpoints were examined in brain 
homogenates from mice treated chronically with morphine to determine whether 
morphine tolerance was associated with changes in  opioid receptor number and G 
protein activation in brain regions that are thought to play a role in the development of 
morphine antinociceptive tolerance (Morgan et al., 2005). 
Methods 
Transgenic mice 
Gαo +/- mice were generated on a pure 129S6 background as described (Duan et 
al., 2007; Lamberts et al., 2011). Mice were group-housed in a facility where lights were 
maintained on a 12 h light/dark cycle (lights on at 07:00) and had unlimited access to 
food and water. Opioid-naïve mice between 10 and 20 weeks of age were utilized for all 
experiments and all testing was performed between 07:00 and 19:00. Male mice were 
used for all behavioral testing; however, due to a limited availability of transgenic mice, 
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both male and female mice were used in the biochemical studies. All protocols were 
approved by the University of Michigan Committee on the Use and Care of Animals and 
experiments were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals as adopted by the National Institutes of Health. 
Behavior 
Hot plate test 
For all tolerance studies, morphine antinociception was evaluated using the 52
o
C 
hot plate test. Hot plate responses were measured by placing mice on a hot plate analgesia 
meter maintained at 52.0 ± 0.2
o
C (Columbus Instruments, Columbus, OH), and the 
latency to lick forepaw(s) or jump was measured. The cutoff latency was set at 60 s to 
prevent tissue damage. Data are plotted as % MPE, where % MPE = (Drug latency – 
Baseline latency) / (Cutoff latency – Baseline latency). 
Acute morphine treatment 
Acute antinociceptive tolerance was induced in male wild type and Go +/- mice 
through administration of a single injection of morphine (128 mg/kg, i.p.; Table 4.1). 
After 6 h, hot plate latencies were recorded immediately prior to a 10 mg/kg morphine 
(i.p.) challenge to determine baseline latency and again 30 min after mice received the 
challenge. Control mice were administered saline (i.p.) 6 h prior to the 10 mg/kg 
morphine challenge. 
To measure acute physical dependence, wild type and Go +/- mice that received 
both the morphine treatment (128 mg/kg, i.p.) and the morphine challenge (10 mg/kg, 
i.p.) were injected 1-2 h later with the general opioid antagonist naltrexone (10 mg/kg, 
subcutaneous; s.c.) to precipitate morphine withdrawal (Table 4.1). Withdrawal behaviors 
were then counted for 30 min as described in below. 
Chronic morphine treatment 
Chronic antinociceptive tolerance was elicited in male wild type and Go +/- mice 
during an 8 day morphine treatment scheme, as follows (Table 4.2). On Day 1, morphine 
antinociception was evaluated using a cumulative dosing paradigm.
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Morphine Dose (mg/kg, i.p.) 
0 h 6 h 7-8 h 
Saline Saline 10 
a 
− 




(10 mg/kg, s.c.) 
 
a
 Hot plate latency (52
o
C) was measured 30 min following morphine. 
b
 Withdrawal 
behaviors were counted for 30 min immediately following naltrexone (NTX).
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Morphine Dose (mg/kg, i.p.) 
Day 1 Days 2 – 7 Day 8 
AM AM PM AM PM 
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(10 mg/kg, s.c.) 
Biochemistry 
     














 Hot plate latency (52
o
C) was measured 30 min following each cumulative injection of 
morphine. 
b
 Hot plate latency (52
o
C) was measured daily 30 min following each injection 
of saline or morphine. 
c




Briefly, mice were given two injections of saline (i.p.) to determine baseline latency, 
followed by three cumulative doses of morphine (10-100 mg/kg, i.p.) in 30 min intervals, 
and hot plate latencies were recorded 30 min after each injection. On Day 2, mice 
received two injections of either 56 or 128 mg/kg morphine (i.p.) separated by ~12 h. 
Control mice received two injections of saline (i.p.) according to the same schedule. 
Twice-daily injections continued for a total of 6 days, ending on Day 7. Hot plate 
latencies were recorded immediately prior to each morning injection of saline or 
morphine to determine baseline latency and again 30 min after mice received the 
injection. On Day 8, morphine antinociception was re-evaluated in the hot plate test using 
cumulative dosing (10-100 or 32-320 mg/kg morphine, i.p.), as above. 
To measure physical dependence, wild type and Go +/- mice that received twice-
daily injections of either 56 or 128 mg/kg morphine were injected with naltrexone        
(10 mg/kg, s.c.) 2-4 h after the final cumulative morphine dose on Day 8 to precipitate 
morphine withdrawal (Table 4.2). Withdrawal behaviors were then counted for 30 min as 
described in Section 2.2.4. 
Morphine withdrawal scoring 
Withdrawal behaviors were scored essentially as described (Divin et al., 2008), 
with slight modifications. Immediately following injection of naltrexone (10 mg/kg, s.c.), 
mice were placed individually in Plexiglas boxes and withdrawal behaviors were 
observed for 30 min. The number of occurrences of jumping, wet dog shakes, and paw 
tremors was recorded in 5 min intervals. The presence of ptosis, chewing, and diarrhea 
was scored during each 5 min interval, as follows: intervals during which the behavior 
was absent were given a score of 0, whereas intervals in which the behavior was present 
were given a score of 1, for a maximum possible score of 6. The % occurrence was then 
calculated for these scored behaviors, where % occurrence = (Observed score / Maximum 
score) × 100. Mice were also weighed immediately preceding and immediately following 
the 30 min observation period, and weight loss was calculated as % decrease in body 
weight (g). Global withdrawal scores were calculated by assigning each withdrawal 
behavior a weighting factor (jumping × 0.8, wet dog shakes × 1, paw tremors × 0.35, 
ptosis × 1.5, chewing × 1.5, diarrhea × 1.5) and summing the resultant values 




Chronic morphine treatment and tissue collection 
For biochemistry studies, male and female wild type and Go +/- mice were 
treated chronically with morphine and brain tissue was removed and stored for future 
analysis (Table 4.2). On Day 1, mice were treated with increasing cumulative doses of 
morphine (10-100 mg/kg, i.p.). Mice were then treated twice-daily for 6 days (Days 2-7) 
with 128 mg/kg morphine (i.p). Control mice received an equivalent number of saline 
injections (i.p.) on Day 1, followed by twice-daily injections of saline (i.p.) on Days 2-7. 
On the morning of Day 8, mice were killed and a midbrain section containing the PAG 
and a hindbrain section containing the RVM were dissected and rapidly frozen in 
isopentane. Brain tissue was then stored at -80
o
C until use. 
Membrane preparation 
Brain tissue was brought to 4
o
C in ice-cold 50 mM Tris, pH 7.4, and homogenates 
were prepared as previously described (Lester and Traynor, 2006). Final membrane 
pellets were resuspended in Tris buffer and assayed immediately. Protein content was 
determined using the BCA protein assay (ThermoFisher Scientific, Waltham, MA). 
Agonist-stimulated [
35
S]GTPS binding assay 
Incorporation of the GTP analog [
35
S]GTPS into activated G subunits was 
monitored in vitro (Traynor and Nahorski, 1995). Brain homogenates (10 g protein) 




S]GTPS binding buffer (50 mM Tris, 5 mM MgCl2, 
100 mM NaCl and 1 mM EDTA, pH 7.4, with 2 mM dithiothreitol, 100 M GDP and  
0.4 U/mL adenosine deaminase) with 0.1 nM [
35
S]GTPγS and a maximal concentration 
(10 M) of either DAMGO or morphine. Non-specific binding was evaluated in the 
presence of 10 M unlabeled GTPS. Reactions were stopped by rapid filtration through 
GF/C filtermats (Whatman, Kent, UK) using a Brandel MLR-24 harvester (Brandel, 
Gaithersburg, MD), and bound radioactivity was determined by liquid scintillation 
counting using a Wallac 1450 MicroBeta counter (PerkinElmer, Waltham, MA). 
Radioligand binding assays 
Total opioid receptor expression was evaluated by incubating brain homogenates 
(50 g protein) in Tris buffer with a saturating concentration (4 ±0.4 nM) of the 
 
80 
radiolabeled opioid antagonist [
3
H]diprenorphine.  Opioid receptor expression was 
defined using the -selective antagonist CTAP (300 nM). To measure high-affinity  
receptor expression, brain homogenates (50 g protein) were incubated in Tris buffer 
with a saturating concentration (12 ± 1.2 nM) of the radiolabeled -selective agonist 
[
3
H]DAMGO. All binding reactions were incubated for 60 min at 25
o
C. Non-specific 
binding was evaluated in the presence of the opioid antagonist naloxone (10 M). 
Binding reactions were stopped by rapid filtration and bound radioactivity was measured 
by liquid scintillation counting, as above. 
Materials 
For behavioral experiments, all drugs were diluted in sterile water. Morphine 
sulfate was from RTI (Research Triangle Park, NC) and naltrexone hydrochloride was 







S]GTPS, were purchased from PerkinElmer. Adenosine deaminase 
was obtained from Calbiochem (San Diego, CA). DAMGO, CTAP, and all other 
chemicals were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. 
Data analysis 
 All data were analyzed using GraphPad Prism 6 (San Diego, CA). Differences 
between groups were evaluated using unpaired t-tests or two-way ANOVA with 
Bonferroni’s post-tests, where appropriate. For all statistical tests, significance was set at 
p<0.05. ED50 (potency) was calculated by fitting the compiled antinociception data to an 
agonist versus response curve (Hill slope=1), and data are reported as the mean (95% CI). 
All other values are reported as the mean ± SEM. 
Results 
Acute morphine tolerance and dependence are unaffected by loss of Go protein  
Wild type and Go +/- mice were first subjected to a short (acute) tolerance 
paradigm (Table 4.1). In wild type mice that had received 128 mg/kg morphine (i.p.) 6 h 
earlier, acute challenge with 10 mg/kg morphine (i.p.) resulted in a significant decrease in 
antinociception in the 52
o
C hot plate test (p<0.01) compared with wild type mice that had 




Figure 4.1: Acute morphine tolerance and dependence. 
(a) Antinociception was measured in the 52
o
C hot plate test 30 min following a challenge 
injection of morphine (10 mg/kg) in wild type and Go +/- mice that were treated with 
either saline (n=6-7) or 128 mg/kg morphine ( n=10) 6 h prior (see Materials and 
Methods). **p<0.01 compared with saline treatment by Bonferroni’s post-test. (b) 
Naltrexone (NTX; 10 mg/kg)-precipitated withdrawal in wild type (n=6) and Go +/- 
mice (n=7) that were treated with 128 mg/kg morphine and challenged with 10mg/kg 
morphine 6 h later (see Materials and Methods). Withdrawal behaviors were scored for a 
period of 30 min (see Materials and Methods). **p<0.01 compared with wild type by 
Students’ t-test. All data are plotted as the mean ± SEM.
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Similarly, morphine-treated Go +/- mice exhibited a significant reduction in morphine 
antinociception (p<0.01), as compared with saline-treated Go +/- mice (Figure 4.1a). 
Thus, a single morphine injection was capable of producing acute tolerance to a challenge 
dose of morphine given 6 h later in both wild type and Go +/- mice, although acute 
morphine antinociception was overall lower in the Go +/- mice (main effect of 
treatment: F(1,29)=19.8, p<0.001; main effect of genotype: F(1,29)=6.7, p=0.015). The 
treatment × genotype interaction was not significant (F(1,29)=0.00, p=0.987).   
Following the morphine challenge (1-2 h), mice that had been previously treated 
with morphine were injected with the general opioid antagonist naltrexone (10 mg/kg, 
s.c.) to precipitate the morphine withdrawal syndrome; withdrawal signs were scored for 
30 min (Table 4.1). Preliminary studies demonstrated that the number of naltrexone-
elicited behaviors was significantly greater following acute morphine treatment than 
following acute saline injection for both wild type and Go +/- mice (data not shown). 
Neither wild type nor Go +/- mice exhibited any jumping behavior when withdrawal 
was precipitated following acute morphine treatment (Figure 4.1b, Jumping). Of the 
additional withdrawal signs scored, only diarrhea was different between genotypes, with 
Go +/- mice exhibiting significantly more diarrhea during acute morphine withdrawal 
than wild type littermates (p<0.01; Figure 4.1b, Diarrhea). In contrast, there were no 
genotype differences observed for other withdrawal signs (p>0.05; Figure 1b), and the 
overall withdrawal syndrome was equivalent between wild type and Go +/- mice 
(p>0.05; Figure 4.1b, Global score). 
Chronic morphine tolerance develops more rapidly in Go +/- mice 
Mice were randomly assigned to receive repeated injections of saline,                 
56 mg/kg/injection morphine or 128 mg/kg/injection morphine (i.p.). In preliminary 
studies, 56 and 128 mg/kg morphine corresponded to the 80% effective dose (ED80) dose 
for antinociception in the 52
o
C hot plate test in wild type and Go +/- mice, respectively 
(data not shown). Twice-daily saline or morphine treatment began on Day 2 and 
continued for 6 days (until Day 7). Hot plate latency was checked daily following each 




Figure 4.2: Chronic morphine tolerance – daily responsiveness. 
Daily hot plate responsiveness in (a) wild type and (b) Go +/- mice treated twice-daily 
with saline, 56 mg/kg morphine or 128 mg/kg morphine (see Materials and Methods). 
Antinociception was measured in the 52
o
C hot plate test 30 min following each morning 
injection of morphine. *p<0.05, **p<0.01, ***p<0.001 compared with antinociception on 
Day 2 within the same chronic treatment group (grey symbols, 56 mg/kg morphine; black 
symbols, 128 mg/kg morphine) by Bonferroni’s post-test. See Table 4.3 for numbers of 
subjects per group. All data are plotted as the mean ± SEM.
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In wild type mice, saline treatment did not alter hot plate latency during the 6 day 
treatment paradigm (p<0.05 compared with Day 2; Figure 4.2a). In contrast, treatment of 
wild type mice with either 56 or 128 mg/kg morphine resulted in a significant reduction 
in antinociception beginning on Day 5 (p<0.05 compared with Day 2; Figure 4.2a). Two-
way ANOVA analysis revealed significant main effects of treatment (F(2,138)=83, 
p<0.001) and day (F(5,138)=4.9, p<0.001), while the treatment × day interaction was not 
significant (F(10,138)=0.65, p=0.764). 
In Go +/- mice, hot plate latency did not change over 6 days of saline treatment 
(p>0.05 compared with Day 2; Figure 4.2b). Go +/- mice exhibited a variable response 
to treatment with 56 mg/kg morphine, with significant decreases in antinociception only 
being observed on Day 4 (p<0.05 compared with Day 2) and Day 6 (p<0.001 compared 
with Day 2; Figure 4.2b). However, treatment of Go +/- mice with 128 mg/kg morphine 
resulted in a consistent reduction in antinociception beginning as early as Day 3 (p<0.01 
compared with Day 2; Figure 4.2b). Statistical analysis by two-way ANOVA revealed 
significant main effects of both treatment (F(2,132)=64, p<0.001) and day (F(5,132)=5.5, 
p<0.001), as well as a significant treatment × day interaction (F(10,132)=2.0, p=0.037). 
Morphine-dose response curves were established in all mice on Day 1 and again 
on Day 8 following twice-daily treatment with saline, 56 mg/kg morphine or 128 mg/kg 
morphine (Figure 4.3). Morphine potency was determined by calculating the ED50, and 
potencies measured on Day 8 were compared with the initial potency measured on Day 1 
(Table 4.3). Treatment with saline did not elicit a change in morphine potency in wild 
type or Go +/- mice (Figure 4.3, Table 4.3). In wild type mice, administration of either 
56 or 128 mg/kg morphine produced a significant decrease in morphine potency, 
indicative of the development of tolerance (Figure 4.3a, Table 4.3). In Go +/- mice 
treated with 56 mg/kg morphine, there was no change in morphine potency between   
Day 1 and Day 8 (Figure 4.3b, Table 4.3). On the other hand, administration of            
128 mg/kg morphine to Go +/- mice resulted in a significant decrease in morphine 




Figure 4.3: Chronic morphine tolerance – dose-response. 
Morphine dose-response curves in (a) wild type and (b) Go +/- mice treated twice-daily 
with saline, 56 mg/kg morphine or 128 mg/kg morphine (see Materials and Methods). 
Morphine antinociception was evaluated in the 52
o
C hot plate test using a cumulative 
dosing procedure in all mice on Day 1 and again in the same mice on Day 8 following 
chronic administration of saline, 56 mg/kg morphine or 128 mg/kg morphine. See    






Table 4.3: Morphine ED50 in the 52
o






Wild type Go +/- 
Morphine ED50 (mg/kg) n Tolerance Ratio 
b
 Morphine ED50 (mg/kg) n Tolerance Ratio 
b
 
Day 1 11.1 (8.70 – 14.2) 26 
 
25.1 (19.7 – 32.0) 25 
 
Day 8 / 
Saline 
20.8 (12.9 – 33.5) 7 1.9 35.9 (20.9 – 61.7) 7 1.4 
Day 8 / 
56 mg/kg Morphine 
54.3 (34.3 - 86.0)* 9 5.1 40.3 (23.8 - 68.1) 8 1.7 
Day 8 / 
128 mg/kg Morphine 
66.9 (42.6 - 105)* 10 6.2 133 (84.9 - 207)* 10 5.6 
 
a
 Chronic treatment refers to the stated agent being administered twice-daily (i.p.) for 6 days (see Materials and Methods). 
b
 Tolerance 
Ratio = Day 8 ED50 / Day 1 ED50. Data are presented as the mean (95% CI). * Significantly different from Day 1 ED50 as determined 
by non-overlapping 95% CIs.
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Withdrawal from chronic morphine is more severe in Go +/- mice 
Immediately following the re-evaluation of morphine potency on Day 8 (2-4 h), 
mice were injected with naltrexone (10 mg/kg, s.c.) to precipitate withdrawal, and 
withdrawal signs were counted during the next 30 min (Table 4.2). In initial testing, 
significantly more naltrexone-elicited behaviors were observed following chronic 
morphine treatment than following an equivalent number of saline injections in both wild 
type and Go +/- mice (data not shown). Compared with wild type littermates, Go +/- 
mice exhibited a significantly greater number of jumps (main effect of genotype: 
F(1,33)=7.4, p=0.010; main effect of treatment: F(1,33)=0.03, p=0.858; genotype × 
treatment interaction: F(1,33)=1.3, p=0.262; Figure 4.4, Jumping) and wet dog shakes 
(main effect of genotype: F(1,33)=4.7, p=0.038; main effect of treatment: F(1,33)=1.4, 
p=0.246; genotype × treatment interaction: F(1,33)=1.4, p=0.246; Figure 4.4, Wet dog 
shakes). In particular, Go +/- mice treated with 56 mg/kg morphine jumped over 4 times 
more often than did wild type mice treated with the same dose of morphine (p<0.05; 
Figure 4.4, Jumping). In contrast, there were no differences between genotypes for any of 
the other counted or scored withdrawal signs (main effect of genotype, p>0.05; Figure 
4.4). Overall, naltrexone-precipitated morphine withdrawal was more severe in Go +/- 
mice in comparison with wild type controls (main effect of genotype: F(1,33)=7.9, 
p=0.008; main effect of treatment: F(1,33)=4.1, p=0.052; genotype × treatment 
interaction: F(1,33)=0.73, p=0.398), especially within the 56 mg/kg morphine treatment 
group (p<0.05; Figure 4.4, Global score).  
Chronic morphine treatment is not associated with changes at the level of  receptors 
To evaluate if morphine tolerance and dependence were associated with changes 
at the receptor level in wild type and Go +/- mice,  opioid function was measured in 
brain homogenates prepared from mice treated chronically with either morphine or saline 
(Table 4.2). After chronic treatment with saline (i.p.) or 128 mg/kg morphine (i.p.), a 
midbrain section containing the PAG and a hindbrain section containing the RVM were 
removed. Membranes prepared from these sections were subjected to radioligand binding 
and [
35
S]GTPS binding analyses to measure  receptor expression (Table 4.4) and  




Figure 4.4: Chronic morphine dependence. 
Naltrexone (NTX; 10 mg/kg)-precipitated withdrawal in in wild type (n=9-10) and     
Go +/- mice (n=9) that were treated twice-daily with either 56 mg/kg morphine or      
128 mg/kg morphine (see Materials and Methods). Withdrawal behaviors were scored for 
a period of 30 min (see Materials and Methods). *p<0.05 compared with wild type mice 

















H]Diprenorphine binding (fmol/mg protein) 12 nM [
3
H]DAMGO binding 
(fmol/mg protein) Wild type Go +/- 
Total  Receptors Total  Receptors Wild type Go +/- 
Midbrain 
Saline 487 ± 36 355 ± 22 432 ± 103 306 ± 77 336 ± 36 267 ± 62 
128 mg/kg Morphine 456 ± 45 298 ± 42 436 ± 7 306 ± 9 326 ± 50 362 ± 27 
Hindbrain 
Saline 336 ± 16 199 ± 7 381 ± 56 274 ± 66 209 ± 12 238 ± 37 
128 mg/kg Morphine 393 ± 35 262 ± 27 349 ± 21 245 ± 25 222 ± 24 223 ± 15 
 
a
 Chronic treatment refers to the stated agent being given twice-daily (i.p.) for 6 days (see Materials and Methods). Data are presented 




Figure 4.5:  Opioid-stimulated G protein activity. 
Midbrain and hindbrain sections were collected from (a) wild type (n=3-4) and (b)      
Go +/- mice (n=3-4) following twice-daily treatment with saline or 128 mg/kg 
morphine, and membranes prepared from these sections were evaluated for 10 M 
DAMGO- or 10 M morphine-stimulated [
35
S]GTPS incorporation (see Materials and 
Methods). Legend in panel (a) also describes panel (b). Agonist-stimulated [
35
S]GTPγS 
binding was calculated by subtracting basal binding from binding that occurred in the 
presence of agonist. Basal [
35
S]GTPS binding was as follows (fmol/mg protein): wild 
type midbrain (saline, 56 ± 6; morphine, 60 ± 3); wild type hindbrain (saline, 42 ± 2; 
morphine, 45 ± 2); Go +/- midbrain (saline, 38 ± 6; morphine, 38 ± 1); Go +/- 
hindbrain (saline, 35 ± 4; morphine, 34 ± 1). All data are presented as the mean ± SEM.
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To measure total opioid receptor expression, brain membranes from wild type and 
Go +/- mice were incubated with a saturating concentration (4nM) of [
3
H]diprenorphine, 
which binds  as well as  and  opioid receptors. Total  receptor number was measured 
by displacing [
3
H]diprenorphine with the -selective antagonist CTAP (300 nM). There 
was no effect of morphine treatment on total opioid receptor or total  receptor 
expression in either midbrain or hindbrain homogenates from wild type and Go +/- mice 
(p>0.05; Table 4.4). Furthermore, there was no effect of chronic morphine treatment on 
high-affinity  opioid receptor expression in either midbrain or hindbrain from wild type 
and Go +/- mice, as measured by 12 nM [
3
H]DAMGO binding (p>0.05; Table 4.4). 
In wild type mice, maximal DAMGO or morphine-stimulated G protein activation 
was unchanged following chronic morphine treatment in either midbrain or hindbrain 
homogenates (p>0.05; Figure 4.5a). Similarly, chronic morphine treatment did not affect 
opioid agonist-stimulated G protein activity in either midbrain or hindbrain of Go +/- 
mice (p>0.05; Figure 4.5b). 
Discussion 
Together, these studies demonstrate that both wild type and Go +/- mice on a 
129S6 background developed antinociceptive tolerance and physical dependence 
following either acute or chronic morphine treatment. While there were no appreciable 
differences between genotypes in the development of these adaptations following acute 
morphine treatment, Go +/- mice appeared to develop tolerance to chronic morphine 
more quickly than their wild type littermates, as measured using the 52
o
C hot plate test. 
In addition, naltrexone-precipitated withdrawal following long-term morphine 
administration was more severe in Go +/- mice. Overall, these studies provide evidence 
that Go protein is protective against morphine tolerance and dependence. 
The transgenic mice utilized in these studies were generated on a pure 129S6 
background, and these mice developed antinociceptive tolerance to morphine in the 52
o
C 
hot plate test following either single or repeated drug administration. Our findings 
contrast with evidence in the literature that 129S6 mice do not develop chronic tolerance 
to morphine in either the tail flick or the hot plate test. This lack of morphine tolerance in 
129S6 mice is thought to be due to a defect in the NMDA receptor (Kolesnikov et al., 
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1998; Nitsche et al., 2002) or GM1 ganglioside (Crain and Shen, 2000). In contrast, 
Bryant et al. (2006) were able to demonstrate chronic morphine tolerance in 129S6 mice 
in both the hot plate and tail flick tests by giving once-daily injections of 10 – 40 mg/kg 
morphine (s.c.) for 6 days followed by a single challenge injection of 7.5 mg/kg 
morphine (s.c.). These authors concluded that the ability to observe morphine tolerance in 
129S6 mice depends upon both the nociceptive test and the dosing regimen employed. 
Indeed, a major difference between the current study and previous reports in 
which chronic morphine tolerance was not observed in 129S6 mice is the dose of 
morphine used. In particular, mice in our study received approximately ED80 doses, either 
56 or 128 mg/kg morphine (i.p.), twice-daily for 6 days. In contrast, mice in previous 
studies received 75 mg morphine (s.c. pellet) over 3 or more days (Kolesnikov et al., 
1998; Nitsche et al., 2002), 2.5 mg/kg morphine (i.p.) once-daily for 5 days (Kolesnikov 
et al., 1998), or 3 mg/kg morphine (s.c.) once-daily for 5 days (Crain and Shen, 2000). 
Therefore, significantly higher doses of morphine are required to elicit antinociceptive 
tolerance in 129S6 mice as compared with more “tolerance-sensitive” strains, such as 
CD-1 or C57BL/6 (Kest et al., 2002a). Moreover, the severity of withdrawal exhibited by 
129S6 mice in our hands was similar to that reported for 129P3/J (129P3) mice and is 
much lower than the extent of withdrawal observed in other strains (Kest et al., 2002b). 
Thus, 129S6 mice may possess certain genetic modifiers that have a dampening effect on 
the development of morphine tolerance and dependence, making them more resistant to 
these chronic adaptations. 
Although the 129S6 mice in this study developed significant tolerance to chronic 
morphine treatment, these behavioral changes were not associated with alterations in  
opioid receptor expression or activity in a midbrain section containing the PAG or a 
hindbrain section containing the RVM. These brain areas are important for both 
morphine antinociception (Yaksh et al., 1988) and the development of morphine 
tolerance (Morgan et al., 2005), and previous reports have shown that  receptor coupling 
to Gi/o proteins is reduced in these regions when rats (Sim et al., 1996; Wang et al., 
2005; Smith et al., 2007) or mice (Sim-Selley et al., 2007) are treated chronically with 
morphine. In contrast, other studies have not found any changes in  opioid receptor 
activation of G proteins in mouse brain or spinal cord following chronic morphine 
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treatment (Contet et al., 2008; Madia et al., 2012). However, Sim-Selley and colleagues 
(2007) have shown that the degree of the reduction in  agonist-stimulated [
35
S]GTPS 
binding is highly dependent on the severity of the morphine treatment regime. This may 
be particularly true in 129S6 mice, which express high levels of  receptors and so may 
possess higher receptor reserve. Moreover, gross dissection of brain regions coupled with 
homogenization in the present study could mask alterations in  opioid receptor signaling 
that occurred within specific neuronal populations (Morgan et al., 2003; Sim-Selley et al., 
2007) and/or subcellular locations (Fabian et al., 2002; Madia et al., 2012). Our results 
also do not rule out the possibility that there are changes downstream of G protein 
activation (Eitan et al., 2003; Bagley et al., 2005a; Fyfe et al., 2010). Nevertheless, it is 
unlikely that changes in  receptor coupling to G proteins alone can fully account for 
behavioral tolerance to morphine in our model (Gintzler and Chakrabarti, 2006; Christie, 
2008). 
Wild type 129S6 mice treated with 56 mg/kg morphine developed significant 
antinociceptive tolerance in the 52
o
C hot plate test. In contrast, although hot plate latency 
was decreased over time in Go +/- mice receiving twice-daily injections of 56 mg/kg 
morphine, there was not a significant rightward shift in the morphine dose-effect curve 
following this treatment paradigm. On the other hand, a similar level of tolerance (~6-
fold) was observed for both wild type and Go +/- mice treated with 128 mg/kg/ injection 
morphine. Whereas morphine responsiveness in wild type mice treated with 128 mg/kg 
morphine was significantly attenuated beginning on Day 5, Go +/- mice treated with the 
same dose of morphine exhibited a decrease in antinociception as early as the second day 
of injections (Day 3). It is unclear why tolerance would develop more quickly in Go +/- 
mice since antinociception is reduced in these animals (Lamberts et al., 2011). However, 
with the 50% reduction in Go protein in Go +/- mice, signaling systems are less 
efficient and therefore have a decreased receptor reserve. This could make Go +/- mice 
more susceptible to the development of morphine tolerance (Morgan and Christie, 2011), 
which is in agreement with the current findings. 
There is the additional complication that Go +/- mice express reduced Go 
protein throughout development. Given that chronic morphine tolerance is characterized 
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by the presence of adaptations at the cellular, synaptic, and neuronal network levels 
(Williams et al., 2001; Christie, 2008), Go +/- mice may possess an unknown 
developmental compensation that causes these adaptations to occur more quickly. One 
initial adaptation to chronic morphine is desensitization, whereby  receptor coupling to 
Gi/o is reduced during the continued presence of drug via receptor phosphorylation and 
recruitment of arrestin (Gainetdinov et al., 2004). However, acute antinociceptive 
tolerance is thought to more closely mimic initial  opioid receptor desensitization 
(Williams et al., 2001; Christie, 2008), and this was not different between wild type and 
Go +/- mice. This suggests that the mechanism by which chronic morphine tolerance 
develops more quickly in Go +/- mice does not involve differential desensitization. 
Compared with wild type littermates, Go +/- mice also demonstrated enhanced 
physical dependence, as measured by the severity of naltrexone-precipitated withdrawal 
following chronic treatment with morphine. Since dependence is presumably a 
homeostatic response to increased signaling, this is opposite to the finding that might 
have been expected. Moreover, previous studies have shown that knockdown of Go 
expression reduces the severity of antagonist-precipitated withdrawal from chronic 
morphine (Sanchez-Blazquez and Garzon, 1994; Kest et al., 2009). On the other hand, 
there are several “anti-withdrawal” systems in the brain that, when activated, serve to 
dampen the severity of morphine withdrawal. Several of these systems, including the 
neuropeptides N/OFQ (Kest et al., 2001) and galanin (Zachariou et al., 2003a), activate 
Gi/o-coupled receptors to oppose morphine withdrawal. In Go +/- mice, these systems 
may have reduced activity such that “pro-withdrawal” systems dominate, thereby leading 
to a worsening of morphine physical dependence. Future studies can address the 
mechanism of the enhancement in morphine dependence in Go +/- mice by evaluating 
various systems that modulate the severity of morphine withdrawal (Valeri et al., 1989; 
Kest et al., 1996; Kest et al., 2001; McNally and Akil, 2002; Georgescu et al., 2003; 
Zachariou et al., 2003a; Bagley et al., 2005b; Hao et al., 2011). 
In conclusion, Go +/- mice, which express ~50% less Go protein, exhibited 
more rapid tolerance and more severe naltrexone-precipitated withdrawal following 
chronic morphine treatment, suggesting that Go signaling offers some protection against 
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morphine antinociceptive tolerance and physical dependence. The differences observed 
were quantitatively minor, which is likely due to the fact that Go +/- mice only express 
one null allele of Gnao1. Nevertheless, the finding that 129S6 mice developed morphine 
tolerance and dependence when administered high doses of morphine indicates that the 
129S6 strain of mice and knockdown of Go may be useful models for evaluating 
characteristics that diminish or enhance morphine tolerance and dependence, 
respectively. The identification of factors that counteract morphine tolerance and 
dependence could help uncover novel targets for the development of opioid analgesics 
that are devoid of these adaptations.
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  Chapter 5
General Discussion 
Summary and significance 
The studies described in this thesis have addressed the role of the G subunit Go 
in both  opioid receptor signaling and opioid-generated behavioral responses. In 
particular, I have examined the requirement for Go expression using a strain of 
transgenic mice that constitutively lacks Go protein. Experiments using these mice 
demonstrated that Go protein couples to the  opioid receptor in vivo and is important 
for the production of opioid antinociception. These studies also showed that Go is 
involved in pathways that mediate morphine antinociceptive tolerance and physical 
dependence, where it serves to counteract the development of these adaptations.  
Additionally, I have evaluated the importance of Go regulation by RGS proteins 
using a second strain of transgenic mice that constitutively expresses Go RGSi subunits. 
Studies in Go +/GS mice demonstrated that endogenous RGS protein activity at Go 
negatively regulates opioid supraspinal antinociception as well as the ability of opioids to 
modulate GABAergic neurotransmission in the PAG. However, the same study also 
revealed a potential novel role of RGS proteins as positive regulators of opioid spinal 
antinociception. 
Overall, my work demonstrates that Go protein plays an important role in opioid 
antinociception, and that RGS proteins regulate this behavior by directly interacting with 
Go subunits and acting as GAPs. These findings are significant in that they highlight the 
RGS:Go interface as a potential target for the development of safer analgesics. 
Specifically, I hypothesize that enhancing Go activity by blocking RGS regulation could 
be viable strategy for enhancing opioid analgesia without increasing unwanted side 
effects. This hypothesis was directly validated by the studies in Go +/GS mice, which 
showed that blocking the interaction between endogenous RGS proteins and Go 
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increases opioid supraspinal antinociception in the hot plate test. The idea that blocking 
RGS regulation might not concurrently increase unwanted side effects was indirectly 
supported by experiments in Go +/- mice demonstrating that Go protein is protective 
against morphine tolerance and dependence. Thus, it can be hypothesized by extension 
that mice with increased Go activity, such as Go +/GS mice, would exhibit reduced 
tolerance and dependence. Nevertheless, future studies are necessary to confirm that 
blocking RGS regulation of Go either reduces or does not alter tolerance and 
dependence to opioids. 
Finally, it has been proposed that combining an RGS inhibitor with an opioid 
partial agonist would preferentially enhance analgesic effects without increasing side 
effects since partial agonists generally have a reduced side effect profile (Clark et al., 
2008). My work also supports this hypothesis, because the phenotypic effect of 
expressing Go RGSi subunits was more substantial in the presence of a partial agonist 
(i.e. morphine) than a full agonist (i.e. methadone). Therefore, future preclinical studies 
should evaluate the combination of an RGS inhibitor and an opioid partial agonist as a 
mechanism for producing effective analgesia with reduced side effects. 
Future directions 
Although my studies in Go knockout and Go RGSi mice have provided new 
evidence regarding the importance of Go for opioid signaling and behavior, there are 
some caveats to be considered. Additionally, my work has raised several unanswered 
questions that should be the subject of further inquiry. The following sections will discuss 
these caveats and remaining questions as they relate to the study of either Gi/o subunits 
or RGS proteins, or to the use of the various experimental models. In addition, I will also 
provide suggestions for how to address such issues in future work. 
Studies in Go knockout mice  
Role of specific Gi/o proteins in opioid-induced behaviors 
My work has shown that Go is a vital intracellular mediator of opioid 
antinociception. However, one of the remaining concerns related to these behavioral 
studies in  Go +/- mice is whether or not Go is the only Gi/o isoform involved in 
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opioid antinociception. Using Go +/- mice, I demonstrated that Go mediates both 
spinal and supraspinal opioid antinociception using the tail withdrawal and hot plate tests, 
respectively. In agreement with previous studies (Raffa et al., 1994; Sanchez-Blazquez et 
al., 1995; Sanchez-Blazquez et al., 2001), I found that a reduction in Go protein 
expression did not alter morphine antinociception in the tail withdrawal test. However, 
evaluation of spinal antinociception elicited by the opioid partial agonist nalbuphine in 
Go +/- mice revealed that Go does mediate this behavior, but that signaling systems are 
more efficient such that a 50% reduction in Go protein was not sufficient to affect 
responses produced by an efficacious agonist such as morphine. Thus, my findings help 
explain why previous studies using antisense ODN knockdown of individual G subunits 
may not have uncovered a role for Go in morphine spinal antinociception until >60% 
local knockdown of Go levels was achieved (Standifer et al., 1996). 
On the other hand, there remains a discrepancy between those previous studies 
that demonstrated a role for Gi2 in morphine spinal antinociception (Raffa et al., 1994; 
Sanchez-Blazquez et al., 1995; Sanchez-Blazquez et al., 2001) and the present work, 
which found no differences in morphine antinociception between wild type and Gi2 -/- 
mice. My studies do not necessarily rule out that other Gi/o subtypes contribute to opioid 
antinociception; rather, they simply indicate that the Go subunit is an important 
mediator of these behaviors. It is possible that other Gi/o subunits play a role or have 
brain region-specific functions, and this could be evaluated using either mice with site-
specific knockdown of Gi/o subunits by RNA interference (RNAi) (Kuhn et al., 2007) or 
conditional Gi/o null mice with inducible and/or local knockout of specific Gi/o 
isoforms (Matthaei, 2007; Castrop, 2010). The use of conditional transgenic mice will be 
considered later on in this section. 
In addition, although my work demonstrates that Go plays a protective role in 
pathways that mediate morphine tolerance and dependence, it does not confirm whether 
Go is the only or even the main Gi/o subunit involved. Given that knockout of Gz has 
also been shown to cause more rapid morphine tolerance in the hot plate test (Hendry et 
al., 2000; Leck et al., 2004), it is possible that these two Gi/o subtypes work in concert to 
counteract adaptations that lead to tolerance or have region-specific roles. Therefore, 
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future studies should examine the development of morphine antinociceptive tolerance and 
physical dependence in transgenic mice null for individual Gi/o subunits or mice with 
RNAi-mediated knockdown of Gi/o proteins. 
Lastly, the role of Gi/o subunits in other  opioid receptor-mediated behaviors, 
such as respiratory depression, constipation, or locomotor activation, was not evaluated in 
the present work. Previous studies have shown that antisense ODN knockdown of Gi2 
did not affect morphine-induced constipation (Raffa et al., 1996), and therefore this raises 
the possibility that Go, or another Gi/o subtype other than Gi2, is responsible for this 
effect of morphine. Similarly, although changes in G protein activity have been shown to 
occur in a model of morphine reward (Narita et al., 2003; Vigano et al., 2003), it is 
unknown which Gi/o subunit, if any, is responsible. To this end, future studies using 
isoform-specific Gi/o knockout mice should be used to determine the contribution of 
individual Gi/o subunits to the various behavioral effects of morphine and other opioids.  
Site of Go control of opioid antinociception  
My demonstration that  opioid receptor coupling to G proteins is reduced in Go 
knockout mice supports the idea that Go plays a key role in the initiation of  opioid 
receptor signaling that eventually leads to antinociception. However, these studies were 
performed in homogenates prepared from whole brain or spinal cord, and therefore they 
do not provide any information about which regions or neuronal populations are 
involved. One way to evaluate which part of the nociceptive pathway is important for the 
production of opioid antinociception mediated specifically by Go is to use 
electrophysiological techniques to measure opioid modulation of synaptic transmission in 
various regions from Go knockout mice. In Go +/GS mice, opioid inhibition of GABA 
neurotransmission was enhanced in the PAG, so it is likely that the opposite result would 
be observed in PAG from Go knockout mice. Nevertheless, opioids produce 
antinociception by acting at several sites along the neuraxis (Cesselin et al., 1999; 
Heinricher and Morgan, 1999; see also Chapter 1 of this thesis), and therefore any 
evaluation of changes in opioid signaling should also include other regions, such as the 
RVM and the spinal cord dorsal horn. 
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Studies in Go RGSi mice 
Role of individual RGS proteins in opioid antinociception 
My work demonstrated, using Go +/GS mice, that endogenous RGS proteins 
modulate opioid antinociception by acting as GAPs at Go. These studies are novel in 
that they show for the first time that RGS proteins exert these effects via direct GAP 
activity at Go and not through some other function, such as scaffolding. Nonetheless, 
one caveat of the Go RGSi model is that it cannot determine which RGS isoform(s) are 
involved in this regulation. A clue as to which RGS protein is involved comes from my 
finding that the direction of this RGS regulation was qualitatively different, with negative 
regulation being observed in the hot plate test and positive regulation occurring in the tail 
withdrawal test. These results mirror previous studies in which RGS9-2 positively or 
negatively regulated morphine antinociception in the same manner, depending on the 
nociceptive test employed (Zachariou et al., 2003b; Papachatzaki et al., 2011). However, 
Zachariou and colleagues ascribed these effects to a scaffolding role of the various 
protein-protein binding domains on RGS9-2, whereas my results suggest that GAP 
activity alone is sufficient to achieve positive or negative RGS regulation. Nonetheless, 
RGS9-2 is a likely candidate contributing to opioid antinociception mediated by Go. On 
the other hand, several other RGS proteins have been implicated in  opioid receptor 
signaling in vitro, including RGS4, RGS8 and RGS19 (Wang et al., 2009; Talbot et al., 
2010; Wang and Traynor, 2012), and these could be important in brain regions where 
RGS9-2 is not expressed or is present at low levels. 
One way to test the hypothesis that RGS9-2, but not other RGS subtypes, 
modulates opioid antinociception is to use RNAi strategies in mice to knock down 
individual RGS isoforms in specific brain regions (Kuhn et al., 2007). An alternate 
approach is to use small molecule RGS inhibitors. Small molecules that target various 
aspects of RGS function are being developed (Roman and Traynor, 2011), and significant 
progress has been made toward the identification and characterization of high potency 
inhibitors of RGS4 (Blazer et al., 2011). Alternatively, the regulation of RGS proteins is 
currently being explored as a way to modify RGS function, for example by altering 
protein degradation (Sjögren and Neubig, 2010). The use of pharmacological 
manipulation of RGS proteins is a therapeutically-relevant method, and studies 
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examining the effects of RGS inhibition (or activation) on opioid antinociception would 
provide important information for drug discovery programs that target the RGS:G 
interface for the treatment of pain (Neubig and Siderovski, 2002). 
Although these studies provide evidence that the RGS:Go interface is a viable 
target for the development of improved pain therapeutics, the specificity of RGS:Go 
complexes for opioid antinociception over other opioid and non-opioid behaviors has not 
been fully addressed here. Thus, future work is needed to determine how targeting this 
interface alters signaling of other neuronal GPCRs that couple to Go, such as dopamine, 
serotonin, adrenergic and muscarinic receptors (Jiang and Bajpayee, 2009). 
RGS function in spinal and supraspinal pathways 
My studies in Go +/GS mice also raise several additional questions that will be 
important to examine in future work. In particular, it is still unclear as to why the 
direction of RGS regulation of opioid antinociception was opposite between the hot plate 
test (supraspinal) and the tail withdrawal test (spinal). Moreover, it is peculiar that 
baseline spinal nociception (endogenous opioid peptide-mediated) and spinal 
antinociception (opioid agonist-mediated) were differentially regulated by RGS proteins 
despite being measured in the same nociceptive test, the tail withdrawal test. An 
understanding of the mechanisms underlying these observations will require several 
parallel and complementary approaches. 
First, opioids in the present study were administered systemically and so will 
activate several spinal and supraspinal pathways simultaneously (Cesselin et al., 1999; 
Heinricher and Morgan, 1999). Thus, one way to begin teasing apart the seemingly 
contradictory findings is to better characterize the specific site(s) of opioid action in    
Go +/GS mice. For example, hot plate and tail withdrawal responses could be evaluated 
following either i.c.v. or intrathecal administration of morphine. Furthermore, the 
contribution of ascending and descending nociceptive pathways to each nociceptive 
response should be tested by specifically ablating either ascending or descending 
projections. This can be accomplished by either manually destroying specific brain areas 
or applying various neurotoxins (Heinricher and Morgan, 1999). 
Secondly, the differences observed between opioid spinal and supraspinal 
antinociception and/or between spinal nociception and antinociception could involve 
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differences in the consequences of RGS GAP activity between nociceptive pathways. 
Specifically, my results can be explained if RGS proteins inhibit  opioid receptor 
signaling in supraspinal networks yet enhance  opioid receptor activity in spinal circuits. 
This may depend upon which signaling pathways are activated by  opioid receptors in 
different populations of neurons, because there is evidence to suggest that RGS proteins 
inhibit signaling to AC and MAPK yet promote intracellular Ca
2+
 responses (Clark et al., 
2011). Thus, if Ca
2+
-dependent pathways are preferentially activated in neurons of the 
spinal cord, this could explain the observed qualitative difference between opioid spinal 
and supraspinal antinociception. 
Indeed, there are known differences in the signaling mechanisms that are 
activated by  opioid receptors between spinal and supraspinal pathways, and these could 
be responsible for the behavioral observations in Go +/GS mice. For example, 
presynaptic  receptors in the PAG activate a voltage-sensitive potassium channel via 
phospholipase A2 (Vaughan et al., 1997), while  receptors in the spinal cord do not 
appear to use this mechanism (Heinke et al., 2011). In contrast, postsynaptic  receptors 
in both the PAG and spinal cord activate GIRK channels and inhibit voltage-gated 
calcium channels (Chieng and Christie, 1994a; Connor et al., 1999; Heinke et al., 2011). I 
have already demonstrated that endogenous RGS proteins negatively regulate opioid 
presynaptic inhibition of GABAergic transmission in PAG neurons. However, the role of 
RGS proteins in the postsynaptic effects of  opioid receptors in the brain and spinal cord 
is not known. Thus,  opioid receptor coupling to these effectors should be evaluated in 
both supraspinal and spinal neurons from Go +/GS mice using electrophysiology and 
other similar spatially- and temporally-resolved methods. 
Furthermore, as opioid antinociception is known to be mediated in part by the 
inhibition of pronociceptive neuropeptide release in the spinal cord (Cesselin et al., 1999; 
see also Chapter 1 of this thesis), it is possible that removal of RGS GAP activity actually 
diminishes this effect rather than producing the expected enhancement. A decrease in the 
ability of opioids to inhibit spinal neuropeptide release from primary afferent nociceptors 
would partially explain why I observed a loss of opioid antinociception in Go +/GS 
mice in the tail flick test. Moreover, opioids have been shown in some cases to facilitate 
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neuropeptide release, such as the enhanced spinal release of cholecystokinin mediated by 
morphine acting at  opioid receptors (Benoliel et al., 1994; Gustafsson et al., 2001). If 
this effect of morphine was enhanced by removal of RGS activity at Go, that too would 
explain my results in Go +/GS mice. Therefore, the release of neuropeptides such as 
substance P and cholecystokinin should be measured in the spinal cord of Go +/GS 
mice. 
Third, the behavioral observations in Go +/GS mice could be due to adaptations 
within other neurotransmitter receptor systems. This is because the Go RGSi mutation 
will increase the lifetime of active Go-GTP and  subunits in any GPCR pathway in 
which Go functions. Therefore, it is possible that the apparent positive regulatory 
function of RGS proteins in spinal pathways is due to a lack of RGS activity within 
pronociceptive receptor systems that signal via Go, such as NOP (Mogil and Pasternak, 
2001). Indeed, NOP activity in the PAG has been shown to inhibit opioid spinal 
antinociception in rats (Scoto et al., 2007), and alterations within this system could 
underlie the reduction in opioid spinal antinociception observed in Go +/GS mice. In 
addition, both adrenergic and serotonergic systems are involved in descending 
antinociceptive pathways (Millan, 2002), and changes within either of these pathways 
could have also contributed to my results in Go +/GS mice. To address these 
possibilities, electrophysiological experiments as well as neurotransmitter release studies 
should be performed in the brain and spinal cord to evaluate NOP, adrenergic, and 
serotonergic signaling. 
Lastly, in addition to blocking RGS GAP activity at Go, the Go RGSi mutation 
will prevent Go binding to RGS proteins from the RA and RL families that have an RH 
domain but exhibit low or no GAP activity (Hollinger and Hepler, 2002). In wild type 
mice, these RGS proteins may either sequester Go, prolonging the lifetime of active  
subunits, or link Go to diverse signaling pathways. In either case, loss of RH domain 
binding to Go, as in Go +/GS mice, would reduce  opioid receptor signaling. To 
evaluate this mechanism, RGS proteins of the RA and RL families could be locally 




Use of nociceptive tests 
My studies have evaluated opioid antinociception in both Go +/- and Go +/GS 
mice using only two noxious stimuli, the tail withdrawal test and the hot plate test, both 
of which are thermal stimulus modalities (Le Bars et al., 2001; Barrot, 2012). Thus, 
another unknown is whether or not Go subunits mediate opioid antinociception to other 
noxious stimuli, such as chemical or mechanical. Although opioids are used to treat a 
wide variety of pain states, not all stimulus modalities are equally blocked by opioid 
analgesic drugs; this can be observed both clinically (Kindler et al., 2011) and 
experimentally (Scherrer et al., 2009). Therefore, from a therapeutic perspective, it will 
be important to understand the role of interactions between  opioid receptors, Go 
subunits, and RGS proteins across several noxious tests. For instance, Go +/- and      
Go +/GS mice could be tested for morphine antinociception against a chemical stimulus, 
such as in the acetic acid stretching assay, or against a mechanical insult, such as in the 
paw pressure test (Le Bars et al., 2001; Barrot, 2012). 
In addition, chronic pain states such as inflammatory or neuropathic pain are more 
clinically-relevant, and therefore the translational value of these studies would be 
enhanced by evaluating these types of sustained nociceptive stimuli. Models of both 
inflammatory and neuropathic pain produce allodynia (perceiving a previously innocuous 
stimulus as being noxious) and hyperalgesia (increased sensitivity to a noxious stimulus), 
which can be measured using standard thermal and mechanical nociceptive tests (Barrot, 
2012). In the case of inflammatory pain, rodents are usually injected in the paw with an 
immunogenic agent such as Freund’s adjuvant or carrageenan, following which allodynia 
and hyperalgesia will be present for several hours. Experimental neuropathic pain in 
rodents is generally induced by ligating the sciatic nerve, which results in lasting 
allodynia and hyperalgesia, depending on the severity of the ligation. Evaluation of these 
pain states in Go +/- and Go +/GS mice would provide valuable information regarding 
the role of G protein signaling in chronic pain and could potentially uncover novel targets 
for the treatment of these debilitating conditions (Rosenblum et al., 2008).  
 
105 
Use of transgenic mouse models 
The crux of my thesis is the use of two transgenic mouse models, one with 
targeted knockout of Gnao1 (Go knockout mice) and the other with targeted knock-in of 
an RGSi mutant Gnao1 allele (Go RGSi mice). Though these models have provided 
novel information regarding the role of Go protein and its regulation in opioid-mediated 
signaling and behavior, their use was associated with two important concerns. First, both 
strains of transgenic mice were constitutive, meaning that expression of the transgene 
was initiated at birth and occurred in all cell types. There are several potential issues with 
transgenic mouse models that utilize constitutive transgene expression, and these will be 
discussed below. Second, the transgenic mice used in the current studies were developed 
on two different 129 sub-strains, and there may be confounds related to these background 
genotypes. 
Constitutive transgene expression 
Although constitutive transgenic models have been useful for the past few 
decades, there are several caveats to consider when using constitutive transgenic mice 
that could potentially complicate the genotype-to-phenotype association (Matthaei, 2007; 
Castrop, 2010). First, depending on the gene that is being manipulated, constitutive 
transgene expression could possibly lead to developmental problems, or even embryonic 
lethality, if the gene is important for normal growth (Matthaei, 2007; Castrop, 2010). 
This is clearly the case for both the Go knockout and the Go RGSi strain utilized in the 
present studies. Specifically, only a few Go -/- mice were obtained for biochemical 
analysis, and Go GS/GS were not viable (Goldenstein et al., 2009). Though neither 
strain was embryonic lethal, these findings clearly demonstrate the function and 
regulation of Go protein is important for mouse development. Indeed, two 
independently-generated strains of Go knockout mice were reported to exhibit multiple 
signaling defects that could potentially underlie the shortened life-span of Go -/- mice. 
For example, Go -/- mice had altered Ca
2+
 current regulation in DRG neurons (Jiang et 
al., 1998) and reduced muscarinic regulation of Ca
2+
 channels in the heart (Valenzuela et 
al., 1997). Moreover, the same strain of Go knockout mice used in the current study has 
previously been shown to exhibit decreased muscarinic regulation of heart rate (Duan et 
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al., 2007). Therefore, it is likely that normal heart and/or neuronal development is altered 
in Go -/- mice such that few of these animals survive until weaning. It is unclear why 
Go GS/GS mice are not viable, although the mechanism in this case may also involve 
the heart. The viability of Go GS/GS mice is the subject of another thesis in this 
department (Kehrl et al., 2012). 
Another issue associated with the use of constitutive transgenic mice is the 
potential for compensatory or developmental changes in genes or signaling pathways 
beyond the gene of interest (Matthaei, 2007; Castrop, 2010). Though my studies 
demonstrated that other Gi/o subtypes were not altered in either Go knockout or       
Go +/GS mice, this represents only a fraction of the number of genes that could be 
changed. Since Go is important for signaling at several neurotransmitter receptors 
(Brown and Sihra, 2008; Jiang and Bajpayee, 2009), it is possible that receptors other 
than the  opioid receptor could be affected in these mice. Indeed, in Go -/- mice, the 
activity of several GPCRs, including dopamine, muscarinic and serotonin receptors, has 
been shown to be reduced (Valenzuela et al., 1997; Jiang et al., 2001; Duan et al., 2007), 
in addition to the observed decrease in  opioid receptor signaling (Jiang et al., 1998; 
Jiang et al., 2001; see also Chapter 2 of this thesis). Moreover, responses to adrenergic 
agonists are enhanced in hippocampus from Go +/GS mice (Goldenstein et al., 2009). 
Thus, a complete evaluation of both Go knockout and Go RGSi mice should include an 
examination of signaling and behavior mediated by other GPCRs to either confirm or 
refute the presence of such compensatory changes. 
To overcome these specific limitations related to the use of constitutive transgene 
expression, there exist several strategies for developing transgenic mice with more 
temporal and/or spatial control over the expression of the transgene (Matthaei, 2007; 
Castrop, 2010). Such models are termed “conditional” because the expression – or lack of 
expression – of a particular gene is dependent upon specifically designed constraints. In 
particular, tissue-specific transgene expression can be obtained using the phage-derived 
Cre/loxP system, which utilizes tissue-specific expression of Cre recombinase to locally 
delete a gene of interest that has been flanked by loxP sites (Gu et al., 1994). Additional 
manipulations, such as the use of a tamoxifen-inducible Cre/estrogen receptor construct, 
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can add temporal control to the classic Cre/loxP system (Sohal et al., 2001). In addition, 
local and inducible transgene expression can be achieved with the use of a tetracycline 
system, which is able to control gene transcription in response to the presence of 
tetracycline (or doxycycline) (Kistner et al., 1996). Ideally, the development of 
conditional Go knockout and Go RGSi mice using one of these response systems 
would overcome the aforementioned limitations of constitutive transgenic strategies 
while also allowing for the examination of the role of Go in specific neuronal cell types. 
Genetics of background strain 
A further concern related to the use of transgenic mouse models is the choice of 
background strain on which the genetically-modified mice are developed. Specifically, it 
is possible that modifier genes unique to the background strain could affect the observed 
phenotype independently of the transgene (Castrop, 2010). This is especially true for 
studies of nociception in mice, because widely different nociceptive phenotypes are 
apparent among commonly used background strains, including C57BL/6 and 129 
(Lariviere et al., 2001; Leo et al., 2008). Thus, the results I obtained in Go knockout and 
Go +/GS mice, which were developed on pure 129S6 and 129S1 backgrounds, 
respectively, may be unique to these background strains. In fact, I demonstrated here that 
the 129S6 mouse strain is relatively resistant to morphine tolerance and dependence, and 
therefore it is possible that different results would have been obtained using mice on a 
pure C57BL/6 background, as these mice are more sensitive to the development of 
morphine tolerance and dependence (Kest et al., 2002a; Kest et al., 2002b). On the other 
hand, 129S1 mice have been shown to exhibit impaired corticolimbic circuit function, 
and since this network is involved in nociceptive processing it could have impacted the 
observed phenotype in Go +/GS mice (Hefner et al., 2008). 
The current recommendation for avoiding confounds due to the choice of 
background genotype is to utilize an F1 hybrid cross between two different congenic 
mutant lines, for example 50% C57BL/6 and 50% 129P3 (Silva et al., 1997). This 
strategy should eliminate some of the non-specific effects due to background genotype, 
and transgenic phenotypes are likely to be more comparable across hybrids than across 
inbred strains. Therefore, another potential improvement to the current studies would be 
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to analyze opioid signaling and behavior in Go knockout and Go +/GS mice generated 
from F1 hybrid crosses. 
Overall conclusions 
In sum, the work outlined in this thesis accomplished the initial goal of better 
understanding the role of the G subunit Go in the behavioral effects of morphine and 
other opioids acting at the  receptor. My studies underscore the importance of the Go 
subunit for normal growth and development, which is not surprising given that it is the 
most abundant Gi/o subtype expressed in the brain (Gierschik et al., 1986) and is also 
enriched in the heart (Valenzuela et al., 1997). In addition, I demonstrated for the first 
time that RGS regulation of Go signaling is mediated via direct interaction of 
endogenous RGS proteins with the Go subunit. This work is relevant to future drug 
development strategies that target the RGS:Go interface as a mechanism of enhancing 
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